Advertisement

General Poster Sessions

Session A ♦  Session B Session C


General Poster Session A: Prostate Cancer


  BRD. A1 :   1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study. (Abstract 9)
Presenting Author: Sten Nilsson - Karolinska University Hospital
  BRD. A2 :   Validation of a genomic classifier for predicting biochemical failure following postoperative radiation therapy in high-risk prostate cancer. (Abstract 10)
Presenting Author: Robert Benjamin Den - Department of Radiation Oncology, Kimmel Cancer Center, Thomas Jefferson University
  BRD. A3 :   Methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer (CRPC). (Abstract 11)
Presenting Author: Kate Lynette Mahon - Royal Prince Alfred Hospital
  BRD. A4 :   Denosumab or zoledronic acid (ZA) therapy on pain interference and cancer-specific quality of life (CSQoL) in patients with castrate-resistant prostate cancer (CRPC) and bone metastases (BM). (Abstract 12)
Presenting Author: Donald Patrick - University of Washington
  BRD. A5 :   Predicting radical prostatectomy outcome: Cell cycle progression (CCP) score compared with primary Gleason grade among men with clinical Gleason less than 7 who are upgraded to Gleason 7. (Abstract 13)
Presenting Author: Matthew R. Cooperberg - University of California, San Francisco
  BRD. A6 :   Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. (Abstract 14)
Presenting Author: Stephane Oudard - Georges Pompidou Hospital
  BRD. A7 :   Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series. (Abstract 15)
Presenting Author: Zachary Benjamin Koloff - University of Michigan Medical School
  BRD. A8 :   Independent validation of a genomic classifier in an at-risk population of men conservatively managed after radical prostatectomy. (Abstract 16)
Presenting Author: Eric A. Klein - Glickman Urological & Kidney Institute, Cleveland Clinic
  BRD. B1 :   Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy. (Abstract 17)
Presenting Author: Jay T. Bishoff - Intermountain Urological Institute
  BRD. B2 :   The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC. (Abstract 18)
Presenting Author: Heather H. Cheng - University of Washington/Fred Hutchinson Cancer Research Center
  BRD. B3 :   Factors associated with biopsy progression on active surveillance. (Abstract 19)
Presenting Author: Christopher J Welty - University of California San Francisco
  BRD. B4 :   Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)?  An analysis of AA phase 3 trials. (Abstract 20)
Presenting Author: Karim Fizazi - Institut Gustave Roussy, University of Paris Sud
  BRD. B5 :   Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302. (Abstract 21)
Presenting Author: Matthew R. Smith - Harvard Medical School and Massachusetts General Hospital
  BRD. B6 :   The PROFILE feasibility study: Genetic prostate cancer risk stratification for targeted screening. (Abstract 22)
Presenting Author: Christos Mikropoulos - Institute of Cancer Research
  BRD. B7 :   Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis. (Abstract 23)
Presenting Author: Pirkko-Liisa Irmeli Kellokumpu-Lehtinen - Department of Oncology, Tampere University Hospital
  BRD. B8 :   Correlation between recurrent chromosomal deletions status obtained on tissue cores and local invasive and systemic prostate cancer growth. (Abstract 24)
Presenting Author: Meike Adam - Department of Urology, University Medical Center Hamburg-Eppendorf
  BRD. B9 :   Tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591. (Abstract 25)
Presenting Author: Michael J. Morris - Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College
  BRD. B10 :   Using ΝΒΝ to predict biochemical relapse following image-guided radiotherapy (IGRT) for intermediate-risk prostate cancer (IR-PCa). (Abstract 26)
Presenting Author: Alejandro Berlin - Department of Radiation Oncology, Princess Margaret Cancer Centre/University Health Network, University of Toronto
  BRD. B11 :   Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. (Abstract 27)
Presenting Author: Evan Y. Yu - Fred Hutchinson Cancer Research Center
  BRD. B12 :   Meta-analysis of randomized trials to study the impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer. (Abstract 28)
Presenting Author: Gurudatta Naik - University of Alabama at Birmingham
  BRD. B13 :   Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA). (Abstract 29)
Presenting Author: Arun Azad - British Columbia Cancer Agency
  BRD. B14 :   Using adjuvant radiotherapy to improve cancer-specific survival  in patients with highly aggressive prostate cancer: Examining recently released criteria. (Abstract 30)
Presenting Author: Firas Abdollah - Department of Urology, Vita-Salute San Raffaele Hospital
  BRD. B15 :   Influence of age on incident diabetes (DM) and cardiovascular disease (CVD) among prostate cancer survivors receiving androgen deprivation therapy (ADT). (Abstract 31)
Presenting Author: Alicia Katherine Morgans Vanderbilt-Ingram Cancer Center
  BRD. B16 :   Post-prostatectomy persisting PSA: Correlation with disease progression and survival in pT3 prostate cancer patients of the ARO 96-02 randomized phase III clinical trial—10 years' follow-up. (Abstract 32)
Presenting Author: Thomas Wiegel - University of Ulm
  BRD. B17 :   Development of novel metastatic prostate cancer cell lines by “Organoid” in vitro culture technology. (Abstract 33)
Presenting Author: Ian Vela - Human Oncology and Pathogenesis Program (HOPP), Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center
  BRD. B18 :   The performance of targeted magnetic resonance imaging/ultrasound fusion biopsy versus random 12-core biopsy for prediction of total prostate cancer tumor volume. (Abstract 34)
Presenting Author: Chinonyerem Okoro - Urologic Oncology Branch, National Cancer Institute at the National Institutes of Health
  BRD. B19 :   Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events. (Abstract 35)
Presenting Author: Matthew R. Smith - Harvard Medical School and Massachusetts General Hospital
  BRD. B20 :   Validation of a whole-blood RNA prognostic signature in metastatic castration-resistant prostate cancer (mCRPC) patients. (Abstract 36)
Presenting Author: William K. Oh - Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
  BRD. B21 :   Forward and inverse-planned intensity-modulated radiotherapy (IMRT) in the CHHiP trial: A comparison of dosimetry and normal tissue toxicity. (Abstract 37)
Presenting Author: Olivia Frances Naismith - Department of Physics, Royal Marsden NHS Foundation Trust
  BRD. B22 :   Predicting progression in patients followed with active surveillance for low-risk prostate cancer. (Abstract 38)
Presenting Author: Itay Aharon Sternberg - Memorial Sloan-Kettering Cancer Center
  BRD. C1 :   Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study.^ (Abstract LBA1)
Presenting Author: Tomasz M. Beer - Oregon Health & Science University-Knight Cancer Institute
  BRD. C2 :   Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). (Abstract 2)
Presenting Author: Charles G. Drake - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  BRD. C3 :   Peptide vaccines with low-dose dexamethasone versus dexamethasone alone for chemotherapy-naive castration resistant prostate cancer: A randomized phase II study. (Abstract 3)
Presenting Author: Hirotsugu Uemura - Department of Urology, Kinki University Faculty of Medicine
  BRD. C4 :   Ten- and 15-year prostate cancer-specific survival in patients with nonmetastatic high-risk prostate cancer randomized to lifelong hormone treatment alone or combined with radiotherapy (SPCG VII). (Abstract 4)
Presenting Author: Sophie Dorothea Fossa - Oslo University Hospital
  BRD. C5 :   Long-term quality of life in high-risk prostate cancer: Results of a phase III randomized trial. (Abstract 5)
Presenting Author: Abdenour Nabid - Centre Hospitalier Universitaire de Sherbrooke
  BRD. C7 :   Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).^ (Abstract 7)
Presenting Author: Robert Dreicer - Cleveland Clinic
  BRD. C8 :   Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers to detect clinically significant disease: Results from the initial screening round of the IMPACT study. (Abstract 8)
Presenting Author: Christos Mikropoulos - Institute of Cancer Research
  BRD. C9 :   Relationship between abiraterone exposure, prostate-specific antigen (PSA) kinetics, and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) . (Abstract 39)
Presenting Author: Steven Xu - Janssen Research & Development, LLC
  BRD. C10 :   Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: A systematic review and meta-analysis. (Abstract 40)
Presenting Author: Arie Carneiro - Department of Urology, ABC Medical School
  BRD. C11 :   Toxicity analysis of lymph node irradiation for prostate cancer patients treated with IMRT. (Abstract 41)
Presenting Author: Matthew E. Johnson - Fox Chase Cancer Center
  BRD. C12 :   The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. (Abstract 42)
Presenting Author: Florence K. Keane - Harvard Radiation Oncology Program, Brigham and Women's Hospital
  BRD. C13 :   Prognostic impact of c-reactive protein (CRP) in metastatic prostate cancer (MPC): A systematic review and meta-analysis. (Abstract 43)
Presenting Author: Gurudatta Naik - University of Alabama at Birmingham
  BRD. C14 :   Circulating microRNAs associated with docetaxel-resistant castration resistant prostate cancer. (Abstract 44)
Presenting Author: Lisa Horvath - Chris O'Brien Lifehouse/Royal Prince Alfred Hospital
  BRD. D1 :   A pilot study of supraphysiologic testosterone (T) and oral etoposide (E) in men with castrate-resistant prostate cancer (CRPC). (Abstract 45)
Presenting Author: Michael Thomas Schweizer - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  BRD. D2 :   Comparison of radical treatment and mortality in patients with nonmetastatic prostate cancer in England and the United States. (Abstract 46)
Presenting Author: Ashwin Sachdeva - Clinical Effectiveness Unit, The Royal College of Surgeons of England
  BRD. D3 :   CCP score and risk stratification for prostate cancer patients at biopsy. (Abstract 47)
Presenting Author: E. David Crawford - University of Colorado Health Science Center
  BRD. D4 :   The impact of body mass index on treatment recommendations for patients with intermediate risk prostate cancer. (Abstract 48)
Presenting Author: Kosj Yamoah - Thomas Jefferson University
  BRD. D5 :   Long-term clinical and toxicity outcomes of hypofractionated intensity-modulated radiation therapy for clinically localized prostate cancer. (Abstract 49)
Presenting Author: Rupesh Kotecha - Department of Radiation Oncology, Cleveland Clinic Foundation
  BRD. D6 :   Impact of obesity on outcomes after definitive dose escalated intensity modulated radiation therapy for localized prostate cancer. (Abstract 50)
Presenting Author: Lora S Wang - Fox Chase Cancer Center
  BRD. D7 :   Population-based comparison of surgical margin status for robotic versus open radical prostatectomy. (Abstract 51)
Presenting Author: Jim C. Hu - University of California, Los Angeles
  BRD. D8 :   Characterization of immune-related adverse events (irAEs) in a phase 3 trial of ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel mCRPC. (Abstract 52)
Presenting Author: Tomasz M. Beer - Oregon Health & Science University-Knight Cancer Institute
  BRD. D9 :   Activity of abiraterone acetate in metastatic patients with castration-resistant prostate cancer (mCRPC) previously treated with ketoconazole: A prospective phase II study from the prostate cancer clinical trials consortium. (Abstract 53)
Presenting Author: Won Kim - University of California, San Francisco
  BRD. D10 :   Results of a phase II trial of docetaxel (DOC), bevacizumab (BEV), and androgen deprivation therapy (ADT) for biochemical relapse (BCR) after definitive local therapy for prostate cancer (PC). (Abstract 54)
Presenting Author: Rana R. McKay - Dana-Farber Cancer Institute
  BRD. D11 :   Results from the seminal vesicle sparing prostatectomy trial. (Abstract 55)
Presenting Author: Scott Michael Gilbert - University of Florida
  BRD. D12 :   Evaluating 18F-16β-fluoro-5α-dihydrotestosterone (FDHT) and FDG PET as prognostic biomarkers for patients (pts) treated with abiraterone acetate (AA). (Abstract 56)
Presenting Author: Jarett Lawrence Feldman - Memorial Sloan-Kettering Cancer Center
  BRD. D13 :   Using MRI/ultrasound fusion biopsy to detect clinically significant prostate cancer in the African American population. (Abstract 57)
Presenting Author: Arvin George - Urologic Oncology Branch, National Cancer Institute at the National Institutes of Health
  BRD. D14 :   Population pharmacokinetic analysis of abiraterone acetate in healthy volunteers and chemotherapy-naive and chemotherapy-pretreated metastatic castration-resistant prostate cancer patients. (Abstract 58)
Presenting Author: Kim Stuyckens - Janssen Research & Development, LLC
  BRD. D15 :   Distribution and geographic accessibility of prostate cancer clinical trials in the United States. (Abstract 59)
Presenting Author: Matt D. Galsky - The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
  BRD. D16 :   The effect of low-dose GTx-758 on free testerone levels in men with metastatic castration resistant prostate cancer (mCRPC). (Abstract 60)
Presenting Author: Evan Y. Yu - University of Washington/Seattle Cancer Care Alliance
  BRD. D17 :   Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience. (Abstract 61)
Presenting Author: Raya Leibowitz-Amit - Princess Margaret Cancer Centre - University Health Network; Department of Medicine, University of Toronto
  BRD. D18 :   Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients. (Abstract 62)
Presenting Author: Bertrand Tombal - Cliniques Universitaires Saint-Luc
  BRD. D19 :   Multiparametric prostate MRI and MRI/ultrasound fusion biopsy as tools to follow prostate cancer progression for men on active surveillance. (Abstract 63)
Presenting Author: Nabeel Shakir - Urologic Oncology Branch, National Cancer Institute at the National Institutes of Health
  BRD. D20 :   Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥80 years-old: Data from PROCEED. (Abstract 64)
Presenting Author: Chadi Nabhan - The University of Chicago
  BRD. D21 :   Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy. (Abstract 65)
Presenting Author: Andrew J. Armstrong - Duke University
  BRD. E1 :   Surgeon volume and disparities in post-operative complications among black men. (Abstract 66)
Presenting Author: Ramdev Konijeti - Division of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School
  BRD. E2 :   Using whole-genome sequencing to implicate the androgen receptor as the predominant driver of DNA breakpoints and fusion events in prostate cancer. (Abstract 67)
Presenting Author: Niall Corcoran - University of Melbourne
  BRD. E3 :   A population-based study of expectant management utilization and its predictors for low-risk prostate cancer. (Abstract 68)
Presenting Author: Matthew J. Maurice - University Hospitals Case Medical Center
  BRD. E4 :   ABO blood group and risk of lethal prostate cancer. (Abstract 69)
Presenting Author: Yuksel Urun - Dana-Farber Cancer Institute
  BRD. E5 :   A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy. (Abstract 70)
Presenting Author: Arnoud J. Templeton - Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre
  BRD. E6 :   ARMOR2: Galeterone in progressive CRPC patients who have failed oral therapy. (Abstract 71)
Presenting Author: Mary-Ellen Taplin - Dana-Farber Cancer Institute
  BRD. E7 :   Gleason score upgrade among 10,282 men who underwent surgery as initial treatment in 2010: A population-based study. (Abstract 72)
Presenting Author: Hong Zhang - University of Rochester Medical Center
  BRD. E8 :   Rectal toxicity after permanent iodine-125 seed implantation: Nationwide cohort study in Japan (J-POPS). (Abstract 73)
Presenting Author: Norihisa Katayama - Okayama University School of Medicine
  BRD. E9 :   Biologic consequences of androgen receptor (AR) activity in MDV3100-resistant LNCaP cells and dependence on AR full length. (Abstract 74)
Presenting Author: Yoshiaki Yamamoto - Vancouver Prostate Centre
  BRD. E10 :   Salvage chemotherapy with carboplatin plus weekly docetaxel in  patients (pts) with castration- and docetaxel-resistant prostate cancer (DRPC): Associations of patient and disease characteristics with overall survival (OS). (Abstract 75)
Presenting Author: Christoph W. Reuter - Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School
  BRD. E11 :   Metabolic response by choline positron emission tomography (cPET) to enzalutamide (ENZ) in castration-resistant prostate cancer (CRPC) patients (pts): Preliminary results of a monoinstitutional prospective study. (Abstract 76)
Presenting Author: Francesca Maines - S. Chiara
  BRD. E12 :   Pattern of occult nodal relapse diagnosed with 18F fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only radiotherapy. (Abstract 77)
Presenting Author: Alexis Lepinoy - Lab of Imaging Engineering (Le2I), UMR CNRS 6306, University of Burgundy
  BRD. E13 :   Sequential monitoring and characterization of circulating tumor cells (CTCs) using the epic sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with recently approved therapeutics. (Abstract 78)
Presenting Author: Roberta Ferraldeschi - The Institue of Cancer Research, The Royal Marsden NHS Foundation Trust
  BRD. E14 :   The molecular and pathway characterization of patients with metastatic castration resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide:  Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). (Abstract 79)
Presenting Author: Eric Jay Small - UCSF Helen Diller Family Comprehensive Cancer Center
  BRD. E15 :   Identifying men at greatest risk of weight gain from androgen deprivation therapy. (Abstract 80)
Presenting Author: Daniel Martin Seible - Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center/Harvard Medical School
  BRD. E16 :   Evaluation of the prostate health index (phi) as a novel biomarker in active surveillance of prostate cancer. (Abstract 81)
Presenting Author: Andrew Eichholz - The Institue of Cancer Research, The Royal Marsden NHS Foundation Trust
  BRD. E17 :   Predictors of choice of treatment in men with localized prostate cancer. (Abstract 82)
Presenting Author: Ramdev Konijeti - Division of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School
  BRD. E18 :   A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC). (Abstract 83)
Presenting Author: Daniel Peter Petrylak - Yale University Medical Center
  BRD. F1 :   Comparing magnetic resonance imaging/ultrasound-fusion biopsy and systemic 12-core transrectal ultrasound biopsy for whole gland pathology. (Abstract 84)
Presenting Author: Daniel Su - Urologic Oncology Branch, National Cancer Institute at the National Institutes of Health
  BRD. F2 :   Transcriptome-wide analysis of matched biopsy and prostatectomy to measure genomic classifiers of prostate cancer progression and field effect. (Abstract 85)
Presenting Author: Beatrice Knudsen - Cedars-Sinai Medical Center
  BRD. F3 :   Degarelix monotherapy versus luteinizing hormone-releasing hormone (LHRH) agonists plus antiandrogen flare protection in the treatment of men with advanced prostate cancer. (Abstract 86)
Presenting Author: Bertrand Tombal - Department of Urology, Cliniques Universitaires Saint-Luc
  BRD. F4 :   Influence of one-year androgen deprivation therapy on lipid and glucose metabolism in patients with newly diagnosed prostate cancer. (Abstract 87)
Presenting Author: Koji Mitsuzuka - Department of Urology, Tohoku University Graduate School of Medicine
  BRD. F5 :   Antigen spread and survival with sipuleucel-T in patients with advanced prostate cancer. (Abstract 88)
Presenting Author: Charles G. Drake - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  BRD. F6 :   Stereotactic body radiosurgery versus intensity modulated radiotherapy for prostate cancer: Comparison of toxicity. (Abstract 89)
Presenting Author: James B. Yu - Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale
  BRD. F7 :   A prospective randomized phase III trial comparing consolidation therapy with or without strontium-89 following induction chemotherapy in androgen-independent prostate cancer. (Abstract 90)
Presenting Author: Jennifer Wang - The University of Texas MD Anderson Cancer Center
  BRD. F8 :   Multidisciplinary clinic evaluation changes prostate cancer stage and risk stratification. (Abstract 91)
Presenting Author: Debasish Sundi - Johns Hopkins Medical Institutions
  BRD. F9 :   Clinical outcomes of  patients (pts) age  80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study). (Abstract 92)
Presenting Author: Antonello Veccia - Santa Chiara Hospital
  BRD. F10 :   Chromosome 8 alterations and PTEN loss in Gleason grade 3 tumor to predict the presence of unsampled grade 4 tumor: Implications for active surveillance. (Abstract 93)
Presenting Author: Bruce J. Trock - The Johns Hopkins University
  BRD. F11 :   A phase II study of 99mTc-trofolastat (MIP-1404) SPECT/CT to identify and localize prostate cancer in high-risk patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (EPLND) compared to histopathology: An interim analysis. (Abstract 94)
Presenting Author: Kevin Mark Slawin - Vanguard Urologic Institute
  BRD. F12 :   Highly functional natural killer (NK) cells as predictive biomarkers associated with long response to castration in newly diagnosed metastatic prostate cancer. (Abstract 95)
Presenting Author: Christine Pasero - Institut Paoli Calmettes CRCM U1068
  BRD. F13 :   Leveraging RB status to define therapy for castrate-resistant prostate cancer. (Abstract 96)
Presenting Author: Renee de Leeuw - Thomas Jefferson University - Kimmel Cancer Center
  BRD. F14 :   Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). (Abstract 97)
Presenting Author: Arun Azad - British Columbia Cancer Agency
  BRD. F15 :   Evaluation of length, maximum Gleason score, and extension of disease at positive surgical margins during radical prostatectomy. (Abstract 98)
Presenting Author: Hooman Djaladat - USC Institute of Urology, University of Southern California
  BRD. F16 :   Clinical activity of abiraterone acetate in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. (Abstract 99)
Presenting Author: Bo Zhao - Cleveland Clinic
  BRD. F17 :   Effect of adjuvant and salvage radiotherapy after radical prostatectomy on urinary continence. (Abstract 100)
Presenting Author: Meike Adam - Department of Urology, University Medical Center Hamburg-Eppendorf
  BRD. F18 :   Comparison of FRAX score to bone mineral density for estimating fracture risk in patients with CRPC on androgen-deprivation therapy (ADT). (Abstract 101)
Presenting Author: Marc Nicolas Bienz - University of Montreal
  BRD. G1 :   Bone and soft tissue response from a phase I/II study with ODM-201 in metastatic castration-resistant prostate cancer (mCRPC).^ (Abstract 102)
Presenting Author: Jorge A. Garcia - Cleveland Clinic
  BRD. G2 :   Positive margin length and Gleason grade of tumor focus at the margin predict for biochemical failure after radical prostatectomy in patients with pT2 prostate cancer. (Abstract 103)
Presenting Author: Jenny N. Nguyen - The University of Texas at Houston Medical School
  BRD. G3 :   Anticancer activity of the selective CYP17A1 inhibitor, VT-464, in preclinical models of castrate-resistant prostate cancer. (Abstract 104)
Presenting Author: Paul Toren - Vancouver Prostate Centre
  BRD. G4 :   Final results of the Montpellier prostate cancer intensity modulated radiotherapy pilot study. (Abstract 105)
Presenting Author: Marie Charissoux - ICM
  BRD. G5 :   One-step ultrasound-based high dose rate (HDR) prostate brachytherapy with dose escalation to the dominant intra-prostatic lesion. (Abstract 106)
Presenting Author: Juanita M. Crook - British Columbia Cancer Agency
  BRD. G6 :   Molecular profiling of advanced refractory prostate cancer. (Abstract 107)
Presenting Author: Rebecca A. Feldman - Caris Life Sciences
  BRD. G7 :   A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). (Abstract 108)
Presenting Author: Fatima H. Karzai - Medical Oncology Branch, National Cancer Institute at the National Institutes of Health
  BRD. G8 :   Cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): Analysis by age group. (Abstract 109)
Presenting Author: Zafar Malik - Clatterbridge Cancer Centre
  BRD. G9 :   Is clinical stage T2C prostate cancer intermediate- or high-risk disease? (Abstract 110)
Presenting Author: Zachary Klaassen - Medical College of Georgia - Georgia Regents University
  BRD. G10 :   A quantitative image analysis model of prostate biopsies for predicting clinical risk in men enrolled in an active surveillance program. (Abstract 111)
Presenting Author: Faisal M Khan - Icahn School of Medicine at Mount Sinai
  BRD. G11 :   ARv567es as detected in circulating tumor cells: An innovative methodology for the detection of a prognostic and therapeutic biomarker. (Abstract 112)
Presenting Author: Avani Atul Shah - National Cancer Institute at the National Institutes of Health
  BRD. G12 :   Predictive factors associated with Gleason score underestimation on prostate biopsy in a monocentric cohort of 3,062 patients treated by mini-invasive radical prostatectomy. (Abstract 113)
Presenting Author: Francois Audenet - Institut Mutualiste Montsouris
  BRD. G13 :   The effect of pathologic T-stage and Gleason score on cancer-specific survival for specimen-confined high-risk prostate cancer. (Abstract 114)
Presenting Author: Lorenzo Tosco - Urology, Department of Development and Regeneration, University Hospitals Leuven
  BRD. G14 :   A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC).^ (Abstract 115)
Presenting Author: Christophe Massard - Institut Gustave Roussy
  BRD. G15 :   Current clinical presentation and treatment of localized prostate cancer in the United States. (Abstract 116)
Presenting Author: Usama Mahmood - The University of Texas MD Anderson Cancer Center
  BRD. G16 :   Preferences for treatment to delay bone metastases (BM) in patients with castration-resistant prostate cancer (CRPC) at high risk of developing BM. (Abstract 117)
Presenting Author: Yi Qian - Amgen, Inc.
  BRD. G17 :   Patient-reported outcomes using a validated LENT-SOMA questionnaire for post-prostatectomy radiotherapy. (Abstract 118)
Presenting Author: Ananya Choudhury - The Christie Hospital NHS Foundation Trust
  BRD. G18 :   Long-term treatment with testosterone undecanoate injections and its effect of prostate cancer incidence in hypogonadal men. (Abstract 119)
Presenting Author: Ahmad Haider - Private Urology Practice
  BRD. G19 :   Molecular and genomic characterization of invasive circulating tumor cells (iCTCs) from men with metastatic castration-resistant prostate cancer (mCRPC). (Abstract 120)
Presenting Author: Terence W. Friedlander - University of California, San Francisco
  BRD. G20 :   The effect of change in PSA velocity on overall survival (OS) in men with biochemically recurrent prostate cancer (BRPC) treated with nonhormonal agents: Combined analysis of four phase 2 trials. (Abstract 121)
Presenting Author: Daniel L. Suzman - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  BRD. G21 :   Evaluation of the Oncotype DX genomic prostate score for risk stratification in prostate cancer patients considered candidiates for active surveilance. (Abstract 122)
Presenting Author: Ganesh K Kartha - Glickman Urological & Kidney Institute, Cleveland Clinic
  BRD. G22 :   Does tumor grade affect the relationship between preoperative prostate-specific antigen (PSA) and biochemical recurrence (BCR)? (Abstract 123)
Presenting Author: Alexander Sankin - Memorial Sloan-Kettering Cancer Center
  BRD. H1 :   Clinical implications of bone scan underuse for patients with high-risk prostate cancer (CaP). (Abstract 124)
Presenting Author: Aaron David Falchook - The University of North Carolina at Chapel Hill
  BRD. H2 :   The sequential use of abiraterone and enzalutamide in metastatic castrate resistant prostate cancer patients: Experience from seven U.K. centers. (Abstract 125)
Presenting Author: Robert Stevenson - University Hospitals Birmingham NHS Foundation Trust
  BRD. H3 :   Results of a phase II trial of abiraterone acetate (AA) combined with dutasteride (DUT) for men with metastatic castration resistant prostate cancer (mCRPC). (Abstract 126)
Presenting Author: Rana R. McKay - Dana-Farber Cancer Institute
  BRD. H4 :   Association of PTEN protein loss with upgrading of prostate cancer from biopsy to radical prostatectomy. (Abstract 127)
Presenting Author: Filipe LF Carvalho - Johns Hopkins University School of Medicine
  BRD. H5 :   Utility of multiparametric MRI at 3 tesla and MRI/ultrasound fusion-guided biopsy in detecting seminal vesicle invasion by prostate cancer. (Abstract 128)
Presenting Author: Dima Raskolnikov - Urologic Oncology Branch, National Cancer Institute at the National Institutes of Health
  BRD. H6 :   Androgen receptor independent acquired mechanisms of resistance to enzalutamide in castration-resistant prostate cancer. (Abstract 129)
Presenting Author: Russell Zelig Szmulewitz - The University of Chicago
  BRD. H7 :   The impact of pelvic magnetic resonance imaging on risk stratification in patients with localized prostate cancer. (Abstract 130)
Presenting Author: David Mitchell Marcus - Department of Radiation Oncology, Winship Cancer Institute of Emory University
  BRD. H8 :   Impact of screening and treatment on racial and ethnic differences in health service use, cost, and mortality among advanced (T3 or greater) prostate cancer patients. (Abstract 131)
Presenting Author: S. Bruce Malkowicz - Department of Urology, Hospital of the University of Pennsylvania,
  BRD. H9 :   Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in progressive metastatic castration resistant prostate cancer (mCRPC). (Abstract 132)
Presenting Author: Ryan Dittamore - Epic Sciences, Inc.
  BRD. H10 :   Feasibility of multimodal molecular characterization of the androgen receptor (AR) in circulating tumor cells (CTCs) from patients with castrate-resistant prostate cancer (CRPC). (Abstract 133)
Presenting Author: David James VanderWeele - University of Chicago
  BRD. H11 :   Identification of biologic and inflammatory markers for predicting clinical responses to sipuleucel-T in CRPC. (Abstract 134)
Presenting Author: Mehmet Faith Hepgur - USC Norris Comprehensive Cancer Center
  BRD. H12 :   Associations between uncertainty, anxiety, and quality of life in men with favorable-risk prostate cancer on active surveillance: Two-and-a-half years' follow-up. (Abstract 135)
Presenting Author: Patricia A. Parker - The University of Texas MD Anderson Cancer Center
  BRD. H13 :   The effect of prior abiraterone (Abi) treatment on subsequent response to docetaxel in men with castrate resistant prostate cancer (CRPC). (Abstract 136)
Presenting Author: Michael Thomas Schweizer - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  BRD. H14 :   The effect of image-guided radiation therapy on rectal and urinary toxicity when radiating the prostatic fossa. (Abstract 137)
Presenting Author: Benjamin Spieler - Icahn School of Medicine at Mount Sinai
  BRD. H15 :   Outcomes after post-operative radiation therapy. (Abstract 138)
Presenting Author: Hao Nguyen - University of California San Francisco
  BRD. H16 :   Preliminary results of a telomerase-based circulating tumor cell assay in prostate cancer patients undergoing definitive radiotherapy. (Abstract 139)
Presenting Author: Kelly M. MacArthur - University of Pennsylvania
  BRD. H17 :   The effect of pathologic T-stage and Gleason score on cancer-specific survival in patients with positive surgical margins after surgery for high-risk prostate cancer. (Abstract 140)
Presenting Author: Lorenzo Tosco - Urology, Department of Development and Regeneration, University Hospitals Leuven
  BRD. H18 :   Urinary function after image-guided intensity modulated radiation therapy (IG-IMRT) of localized prostate cancer. (Abstract 141)
Presenting Author: Edward Obedian - Advanced Radiation Centers of New York
  BRD. J1 :   The role of IL-23 in regulating metastatic prostate cancer through STAT-3/ROR-gamma signaling. (Abstract 142)
Presenting Author: Nasser Ghaly Yousif - Colorado University
  BRD. J2 :   Prevalence of fractures among men with stage IV prostate cancer (S4PC). (Abstract 143)
Presenting Author: Abdulla M. Abdulhalim - Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland
  BRD. J3 :   Optimal testosterone suppression on medical ADT should strive to suppress free testosterone levels, to levels similar to orchiectomy: What is that value? (Abstract 144)
Presenting Author: Evan Y. Yu - University of Washington/Seattle Cancer Care Alliance
  BRD. J4 :   AXIN2 and prostate cancer recurrence after radical prostatectomy. (Abstract 145)
Presenting Author: Brian Robin Hu - University of Southern California Institute of Urology
  BRD. J5 :   The effects of anticoagulant use in high-risk prostate cancer treated with radiotherapy on overall survival and biochemical control. (Abstract 146)
Presenting Author: Stephen G. Chun - Department of Radiation Oncology, UT Southwestern Medical Center
  BRD. J6 :   A feasible and time-efficient adaption of the neurosafe intraoperative frozen section technique to robotic-assisted radical prostatectomy. (Abstract 147)
Presenting Author: Burkhard Beyer - Martini-Clinic, Prostate Cancer Center Hamburg
  BRD. J7 :   A randomized phase I/II study to examine the contribution of carboplatin to cabazitaxel for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) with and without anaplastic features. (Abstract 148)
Presenting Author: Paul Gettys Corn - The University of Texas MD Anderson Cancer Center
  BRD. J8 :   Increasing use of radical prostatectomy for lower-risk prostate cancer in Denmark. (Abstract 149)
Presenting Author: M. Andreas Roeder - Copenhagen Prostate Cancer Center, Rigshospitalet
  BRD. J9 :   PSA patterns during off-time treatment period in patients undergoing intermittent androgen deprivation: Is PSA doubling time reliable in every case? (Abstract 150)
Presenting Author: Rafael Sanchez-Salas - Institut Mutualiste Montsouris
  BRD. J10 :   Effect of a genomic classifier on adjuvant radiation recommendations after prostate cancer surgery. (Abstract 151)
Presenting Author: Ketan K. Badani - Department of Urology, Columbia University College of Physicians & Surgeons
  BRD. J11 :   Feasibility of docetaxel-prednisone (DP) in frail elderly (age 75 and older) patients with castration-resistant metastatic prostate cancer (CRMPC): GERICO10-GETUG P03 trial led by Unicancer. (Abstract 152)
Presenting Author: Loic Mourey - Institut Claudius Regaud
  BRD. J12 :   Long-term oncologic outcomes of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localized, high-risk prostate cancer. (Abstract 153)
Presenting Author: Jonathan L Silberstein - Tulane University School of Medicine
  BRD. J13 :   In vitro reproduction and explanation of an abiraterone acetate withdrawal phenomenon. (Abstract 154)
Presenting Author: Paul Thelen - Georg-August-University
  BRD. J14 :   Methylation-guided stratification of patients with high-risk prostate cancer for the prediction of clinical failure. (Abstract 155)
Presenting Author: Kirill Litovkin - Laboratory of Biosignaling & Therapeutics, Departement of Cellular and Molecular Medicine, KU Leuven
  BRD. J15 :   Modeling acute urinary toxicity after radiotherapy for prostate cancer. (Abstract 156)
Presenting Author: Viviana Carillo - Fondazione Centro San Raffaele
  BRD. J16 :   Does adjuvant treatment affect survival in patients with positive lymph nodes at radical prostatectomy? (Abstract 157)
Presenting Author: Catherine R. Harris - Department of Radiology, University of California, San Francisco
  BRD. K1 :   The enzymology of the selective CYP17 lyase inhibitor, VT-464, and its effects in castration-resistant prostate cancer (CRPC) models. (Abstract 158)
Presenting Author: William R. Moore - Viamet Pharmaceuticals, Inc.
  BRD. K2 :   Clinical activity of enzalutamide against metastatic castration-resistant prostate (mCRPC) cancer in patients who have progressed on abiraterone acetate: The Princess Margaret experience. (Abstract 159)
Presenting Author: Francisco Emilio Vera-Badillo - Princess Margaret Cancer Centre - University Health Network; Department of Medicine, University of Toronto
  BRD. K3 :   Patient-reported sexual outcomes and potency following proton therapy for the management of prostate cancer. (Abstract 160)
Presenting Author: Bradford S. Hoppe - University of Florida Department of Radiation Oncology and University of Florida Proton Therapy Institute
  BRD. K4 :   Proton therapy for prostate cancer: An analysis of rectal toxicity outcomes at University of Florida Proton Therapy Institute (UFPTI). (Abstract 161)
Presenting Author: Rovel J. Colaco - University of Florida Proton Therapy Institute
  BRD. K5 :   Incidence, distribution, and outcomes of node positive patients at radical prostatectomy: Manitoba Prostate Center experience. (Abstract 162)
Presenting Author: Kamaljot Singh Kaler - University of Manitoba
  BRD. K6 :   Using a combination of urine and plasma biomarkers for the development of a scoring sytem that can diagnose and predict prognosis of prostate cancer. (Abstract 163)
Presenting Author: Maher Albitar - NeoGenomics Laboratories
  BRD. K7 :   Greatest percent involved core length and the risk of death from prostate cancer in men with highest Gleason score 7 or higher. (Abstract 164)
Presenting Author: Matthew David Cheney - Harvard Radiation Oncology Program
  BRD. K8 :   EpCAM expression in lymph node and bone metastases of prostate carcinoma: A pilot study. (Abstract 165)
Presenting Author: Hilde Hoving - Department of Urology, University Medical Center Groningen, University of Groningen
  BRD. K9 :   The effect of prostate brachytherapy technique on quality of life outcomes: 5-year outcomes of a prospective cohort study. (Abstract 166)
Presenting Author: James Austin Talcott - Mount Sinai Health System
  BRD. K10 :   Perceptions of radiation oncologists and urologists on the type of evidence that informs and changes the clinical practice of prostate cancer. (Abstract 167)
Presenting Author: Sophia D Delpe - Yale New Haven Hospital
  BRD. K11 :   Pelvic exenteration in patients with nonmetastatic, locally advanced castration-resistant prostate cancer. (Abstract 168)
Presenting Author: Timothy F. Donahue - Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center
  BRD. K12 :   An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC). (Abstract 169)
Presenting Author: Fairooz F. Kabbinavar - Institute of Urologic Oncology, David Geffen School of Medicine at the University of California, Los Angeles
  BRD. K13 :   Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer. (Abstract 170)
Presenting Author: Bobby Chi-Hung Liaw - The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
  BRD. K14 :   The effect of [-2]proPSA and prostate health index (phi) on the accuracy of the prediction of initial and repeat prostate biopsies compared to tPSA and percent fPSA in young men (age 65 or younger). (Abstract 171)
Presenting Author: Martin Boegemann - Department of Urology, University of Muenster
  BRD. K15 :   Patterns and trends in management of locoregional prostatic adenocarcinoma with PSA ≥20 ngm/ML. (Abstract 172)
Presenting Author: Jerry J Trulson - University of Missouri-Columbia
  BRD. K16 :   Focal nodular prostatic peripheral zone enhancement on CT to predict clinically significant (Gleason 4+3 and higher) prostate cancer. (Abstract 173)
Presenting Author: Daniel I. Glazer - University of Michigan
  BRD. K17 :   Biochemical response to ketoconazole therapy in post-chemotherapy mCRPC patients. (Abstract 174)
Presenting Author: M. Andreas Roeder - Copenhagen Prostate Cancer Center, Rigshospitalet
  BRD. K18 :   Prostatectomy at high- versus low-volume centers: A decision analysis. (Abstract 175)
Presenting Author: Afsaneh Barzi - USC Norris Comprehensive Cancer Center
  BRD. K19 :   Real-world utilization of the novel AR-targeted therapies in mCRPC management: An electronic medical records retrospective study. (Abstract 176)
Presenting Author: A. Oliver Sartor - Tulane Cancer Center
  BRD. K20 :   Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC). (Abstract 177)
Presenting Author: Himisha Beltran - Department of Medicine, Institute for Precision Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital
  BRD. K21 :   Evidence for circulating tumor cell (CTC) alkaline phosphatase (AP) expression in men with bone-metastatic castration-resistant prostate cancer (CRPC) during abiraterone acetate treatment. (Abstract 178)
Presenting Author: Andrew J. Armstrong - Duke University
  BRD. K22 :   Leveraging the DNA damage and transcriptional-regulatory roles of PARP-1 as a means to improve prostate cancer therapy. (Abstract 179)
Presenting Author: Matthew Joseph Schiewer - Kimmel Cancer Center at Thomas Jefferson University
  BRD. L1 :   Predicting positive bone marrow biopsies (BMBs) in patients (PTS) with advanced prostate cancer (APC). (Abstract 180)
Presenting Author: David Lorente - The Institue of Cancer Research, The Royal Marsden NHS Foundation Trust
  BRD. L2 :   An automated, sensitive, high-throughput biomarker protocol for tissue microarrays containing archival prostate specimens: The prognostic potential of an ERG EMT panel. (Abstract 181)
Presenting Author: Mick D. Brown - Faculty Institute of Cancer Sciences
  BRD. L3 :   A population-based study of factors associated with post-prostatectomy radiation therapy utilization. (Abstract 182)
Presenting Author: Matthew J. Maurice - University Hospitals Case Medical Center
  BRD. L4 :   Impact of prior radiation treatment (tx) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts). (Abstract 183)
Presenting Author: Steven E. Finkelstein - 21st Century Oncology, Translational Research Consortium
  BRD. L5 :   Comprehensive geriatric assessment (CGA) in men age 70 or over with localized prostate cancer. (Abstract 184)
Presenting Author: Georgina E.C. Osborne - Sussex Cancer Centre
  BRD. L6 :   Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts). (Abstract 185)
Presenting Author: Nicholas J. Vogelzang - Comprehensive Cancer Centers of Nevada
  BRD. L7 :   Accuracy of NaF PET/CT scan to detect bone metastases in CRPC. (Abstract 186)
Presenting Author: Modar Alom - Associated Medical Professionals
  BRD. L8 :   Clinical characteristics and outcomes of patients with prostate cancer and parenchymal brain metastases (PBM). (Abstract 187)
Presenting Author: Richard M. Bambury - Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College
  BRD. L9 :   Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer (mCRPC): Results from an expanded access program. (Abstract 188)
Presenting Author: David Thomson - Royal Preston Hospital
  BRD. L10 :   Response of blood flow to hyperthermia in human prostate tumors: Opportunities for enhanced radiation effect and drug delivery. (Abstract 189)
Presenting Author: Mark Hurwitz - Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University
  BRD. L11 :   Phase II study of weekly cabazitaxel for "unfit" metastatic castration resistant prostate cancer patients progressing after docetaxel treatment: Preliminary toxicity analysis (SOGUG-CABASEM trial). (Abstract 190)
Presenting Author: Miguel Angel Climent Duran - Fundacion Instituto Valenciano de Oncología
  BRD. M1 :   The role of FSH in castration-induced adipogenesis and cardiovascular diseases: Highlighting differences between orchiectomy, GNRH agonists, and antagonists. (Abstract 191)
Presenting Author: Jehonathan H. Pinthus - McMaster University
  BRD. M2 :   The effect of selective JAK2 inhibitor SAR302503 on tumorigenic STAT3 signaling in human prostate cancer in vivo. (Abstract 192)
Presenting Author: Dayson Moreira - City of Hope Comprehensive Cancer Center
  BRD. M3 :   Diagnostic value of biparametric MRI as an adjunct to PSA-based detection of prostate cancer. (Abstract 193)
Presenting Author: Soroush Rais-Bahrami - Urologic Oncology Branch, National Cancer Institute at the National Institutes of Health
  BRD. M4 :   Clinical characteristics and management of late symptom flare following stereotactic body radiation therapy for clinically localized prostate cancer. (Abstract 194)
Presenting Author: Jennifer Ai-Lian Woo - Georgetown University Medical Center
  BRD. M5 :   Bother following stereotactic body radiation therapy for clinically localized prostate cancer. (Abstract 195)
Presenting Author: Onita Bhattasali - Georgetown University Hospital
  BRD. M6 :   Urinary obstruction following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. (Abstract 196)
Presenting Author: W. Tristram Arscott - University of Vermont College of Medicine

General Poster Session B: Prostate, Penile, Urethral, Urothelial, and Testicular Cancers


  BRD. A1 :   Epigenetic profiling of prostate cancer tissue to identify men with high-risk disease. (Abstract 197)
Presenting Author: Leander Van Neste - Maastricht University
  BRD. A2 :   Heterogeneity of prostate-specific membrane antigen (PSMA) expression in classic and apoptotic circulating tumor cells (CTC) in metastatic castration-resistant prostate cancer (mCRPC). (Abstract 198)
Presenting Author: Karen A. Autio - Memorial Sloan-Kettering Cancer Center
  BRD. A3 :   Circadian dysrhythm and advanced prostate cancer. (Abstract 199)
Presenting Author: Lorelei A. Mucci - Harvard School of Public Health
  BRD. A4 :   Is there an anti-androgen withdrawal effect with enzalutamide? (Abstract 200)
Presenting Author: Alejo Rodriguez-Vida - Guy's and St Thomas' NHS Foundation Trust
  BRD. A5 :   PSMA, EpCAM, VEGF, and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy. (Abstract 201)
Presenting Author: Hilde Hoving - Department of Urology, University Medical Center Groningen, University of Groningen
  BRD. A6 :   Biochemical response to enzalutamide therapy in patients with mCRPC following docetaxel and abiraterone treatment. (Abstract 202)
Presenting Author: M. Andreas Roeder - Copenhagen Prostate Cancer Center, Rigshospitalet
  BRD. A7 :   Validation of differential expression of microRNA profiles in prostate cancer specimens. (Abstract 203)
Presenting Author: Nikhil Waingankar - The Arthur Smith Institute for Urology, North Shore-Long Island Jewish Health System
  BRD. A8 :   Circulating tumor cell (CTC) enumeration in patients with metastatic neuroendocrine prostate cancer (NEPC) and castration-resistant prostate cancer (CRPC). (Abstract 204)
Presenting Author: Gurveen Kaur - Weill Cornell Medical College
  BRD. B1 :   Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC). (Abstract 205)
Presenting Author: Scott T. Tagawa - Weill Cornell Medical College
  BRD. B2 :   The expression levels of microRNAs that have the androgen receptor in localized prostate cancer as a target. (Abstract 206)
Presenting Author: Katia Ramos Moreira Leite - Laboratory of Medical Research, Urology Department, University of São Paulo Medical School
  BRD. B3 :   Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: The Zoledronic Acid/Androgen Blockade Trial on Prostate Cancer (Zabton-PC) study. (Abstract 207)
Presenting Author: Satoru Ueno - Kanazawa University Graduate School of Medical Science
  BRD. B4 :   Testosterone replacement therapy in men with prostate cancer after proton therapy. (Abstract 208)
Presenting Author: Curtis Bryant - University of Florida Proton Therapy Institute
  BRD. B5 :   CK- and small nuclear size circulating tumor cell (CTCs) phenotypes in metastatic castration-resistant prostate cancer (mCRPC). (Abstract 209)
Presenting Author: Roberta Ferraldeschi - The Institue of Cancer Research, The Royal Marsden NHS Foundation Trust
  BRD. B6 :   Whole pelvic irradiation for prostate cancer patients with a biochemical relapse following radical prostatectomy: The era of robot-assisted minimally invasive surgery. (Abstract 210)
Presenting Author: Jae-Sung Kim - Department of Radiation Oncology, Seoul National University Bundang Hospital
  BRD. B7 :   Physician referral patterns among men with advanced prostate cancer. (Abstract 211)
Presenting Author: Candice Yong - Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland
  BRD. B8 :   Spironolactone: A selective androgen receptor modulator in castration-resistant prostate cancer. (Abstract 212)
Presenting Author: Philippe Barthelemy - INSERM_S1113
  BRD. B9 :   IDH1 mutation in prostate cancer: R132H and beyond. (Abstract 213)
Presenting Author: Amber Lea Flaherty - H. Lee Moffitt Cancer Center & Research Institute
  BRD. B10 :   Clinical outcomes of patients (pts) age 60 or younger treated with docetaxel (DOC) for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (CYCLOP study). (Abstract 214)
Presenting Author: Antonello Veccia - Santa Chiara Hospital
  BRD. B11 :   A closer look at extraprostatic extension (EPE): Evaluation of PSA relapse rates following prostatectomy (RP) for pT3aN0 prostate cancer with or without margin involvement. (Abstract 215)
Presenting Author: John Morgan Watkins - Bismarck Cancer Center
  BRD. B12 :   Clinical activity of enzalutamide pre- and post-docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). (Abstract 216)
Presenting Author: Rosa Nadal - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  BRD. B13 :   Phase I trial of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in combination with docetaxel (DTX) in patients (pts) with advanced solid tumors, including castration-resistant prostate cancer (CRPC). (Abstract 217)
Presenting Author: John Sarantopoulos - Institute for Drug Development, The University of Texas Health Science Center at San Antonio
  BRD. B14 :   A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer. (Abstract 218)
Presenting Author: Michelle A. Ojemuyiwa - Walter Reed National Military Medical Center
  BRD. B15 :   Clinical and biologic factors for immune response to sipuleucel-T (SipT) for metastatic castrate-resistant prostate cancer (mCRPC). (Abstract 219)
Presenting Author: Mehmet Faith Hepgur - USC Norris Comprehensive Cancer Center
  BRD. B16 :   Simultaneous cone beam CT scanning during prostate radiotherapy to produce clinically useful images. (Abstract 220)
Presenting Author: Ananya Choudhury - The Christie Hospital NHS Foundation Trust
  BRD. B17 :   Preclinical efficacy of growth hormone-releasing hormone antagonist mia-602 for androgen-dependent and castration-resistant human prostate cancer. (Abstract 221)
Presenting Author: Ferenc G. Rick - Miami VA Medical Center
  BRD. B18 :   Pain palliation as an oncology label indication: Lessons learned in custirsen phase III development. (Abstract 222)
Presenting Author: Tomasz M. Beer - Oregon Health & Science University-Knight Cancer Institute
  BRD. B19 :   Impact of number of lines of therapy following docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC). (Abstract 223)
Presenting Author: Guru Sonpavde - UAB Comprehensive Cancer Center
  BRD. B20 :   Patient risk factors and pegfilgrastim use in cabazitaxel treated prostate cancer pateints in an academic setting. (Abstract 224)
Presenting Author: Marina Dusevic Kaymakcalan - Dana-Farber Cancer Institute
  BRD. B21 :   Dehydroepiandrosterone metabolism in fresh human prostate: A feasibility study. (Abstract 225)
Presenting Author: Cesar E. Ercole - Glickman Urological & Kidney Institute, Cleveland Clinic
  BRD. B22 :   Bicalutamide (150 mg) monotherapy versus LHRHa as neoadjuvant treatment in intermediate- and high-risk prostate cancer: A case matched study. (Abstract 226)
Presenting Author: Darren M. Mitchell - Northern Ireland Cancer Centre
  BRD. C1 :   Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder preserving combined modality therapy for muscle-invasive bladder cancer: A pooled analysis of RTOG 9906 and 0233. (Abstract 284)
Presenting Author: Timur Mitin - Massachusetts General Hospital
  BRD. C2 :   Somatic genomic alterations in urothelial cancer: Results of the Cancer Genome Atlas (TCGA) bladder cancer (BC) analysis. (Abstract 285)
Presenting Author: Jonathan E. Rosenberg - Memorial Sloan-Kettering Cancer Center
  BRD. C3 :   Improved outcomes following centralization of cystectomy services in the United Kingdom. (Abstract 286)
Presenting Author: Prashant Patel School of Cancer Sciences, University of Birmingham
  BRD. C4 :   The initial report of RTOG 0524: Phase I/II trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation following transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer. (Abstract LBA287)
Presenting Author: M. Dror Michaelson - Massachusetts General Hospital Cancer Center
  BRD. C5 :   Premature termination of genitourinary cancer clinical trials. (Abstract 288)
Presenting Author: Kristian D. Stensland - Department of Urology, Icahn School of Medicine at Mount Sinai
  BRD. C6 :   Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor. (Abstract 363)
Presenting Author: Stephanie Anne Holler Howard - Dana-Farber Cancer Institute
  BRD. C7 :   Multicenter sequential phase II study of flavopiridol plus oxaliplatin (Alvocidib) with or without 5-FU and leucovorin (LV) for patients (pts) with refractory germ cell tumors (GCT) including late relapse (LR). (Abstract 364)
Presenting Author: Darren Richard Feldman - Memorial Sloan-Kettering Cancer Center
  BRD. C8 :   Patterns of relapse in poor-prognosis germ cell tumors in the GETUG 13 trial: Implications for assessment of brain progression. (Abstract 365)
Presenting Author: Yohann Loriot - Department of Medical Oncology, Institut Gustave Roussy
  BRD. C9 :   Prospective evaluation of low-dose ketoconazole plus hydrocortisone (HC) in chemotherapy-pretreated castration-resistant prostate cancer (CRPC) patients. (Abstract 227)
Presenting Author: Ernest N. Lo - Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center
  BRD. C10 :   Primary care physician (PCP) referral patterns for prostate cancer (PC) patients: Web-based survey. (Abstract 228)
Presenting Author: Rajitha Sunkara - St. Elizabeth’s Medical Center
  BRD. C11 :   Effects of testosterone deficiency or manipulation on prostate cancer. (Abstract 229)
Presenting Author: Aksam Yassin - Institute for Urology and Andrology
  BRD. C12 :   Transurethral (TURP) biopsy of suspected anterior prostate cancers identified by MRI: Pilot study of a novel technique. (Abstract 230)
Presenting Author: Shawn Dason - Division of Urology, McMaster University
  BRD. C13 :   Exploration of alternative digit ratios as a predictor of prostate cancer aggressiveness. (Abstract 231)
Presenting Author: Michael Stolten - Tulane University School of Medicine
  BRD. C14 :   Compliance of subjects using electronic patient-reported outcomes (ePRO) in multinational prostate trials. (Abstract 232)
Presenting Author: Susan M. Dallabrida - PHT Consulting Services
  BRD. D1 :   Familial clustering of prostate cancer (Pca) cases in a nonselected south European population (sEp). (Abstract 233)
Presenting Author: Ignacio Gil-Bazo - Department of Medical Oncology, Clínica Universidad de Navarra
  BRD. D2 :   Quality improvement opportunities in prostatectomy care in a regional hospital-based urologic quality collaborative. (Abstract 234)
Presenting Author: John L. Gore - University of Washington, School of Medicine
  BRD. D3 :   Meaningful survival after cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): The Spanish experience. (Abstract 235)
Presenting Author: Iria Gonzalez Maeso - Hospital del Mar
  BRD. D4 :   Experience with artificial urinary sphincter implantation in men who underwent prior pelvic radiation therapy for prostate cancer. (Abstract 236)
Presenting Author: Sameer Jhavar - Texas A&M College of Medicine, Scott and White
  BRD. D5 :   Phase I clinical study of cabazitaxel plus prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in a Japanese population. (Abstract 237)
Presenting Author: Shunji Takahashi - The Cancer Institute Hospital of Japanese Foundation for Cancer Research
  BRD. D6 :   A predicitve algorithm for response to abiraterone in metastatic castration relapsed prostate cancer (CRPC). (Abstract 238)
Presenting Author: Mehran Afshar - Queen Elizabeth Hospital
  BRD. D7 :   The natural history of bone metastases in castrate-resistant prostate cancer. (Abstract 239)
Presenting Author: Robert James Pell - University College Hospital London
  BRD. D8 :   Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC). (Abstract 240)
Presenting Author: Gurprataap Singh Sandhu - Universtiy of Pittsburgh Medical Center
  BRD. D9 :   Isoflavones in Japanese and Caucasian men with prostate cancer in Hawaii. (Abstract 241)
Presenting Author: Takashi Fukagai - Showa University School of Medicine
  BRD. D10 :   Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D). (Abstract 242)
Presenting Author: Zafar Malik - Clatterbridge Cancer Centre
  BRD. D11 :   A multicenter phase I study of cabazitaxel (Cbz), mitoxantrone (Mito), and prednisone (Pred) (CAMP) for chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC). (Abstract 243)
Presenting Author: Rahul Raj Aggarwal - University of California, San Francisco
  BRD. D12 :   Increase in bone scan index during abiraterone treatment in relation to reduced survival in mCRPC patients. (Abstract 244)
Presenting Author: Mariana Reza - Department of Clinical Physiology, Clinical Sciences, Malmo, Lund University
  BRD. D13 :   Immune impact induced by PSA-tricom, a therapeutic vaccine for prostate cancer. (Abstract 245)
Presenting Author: Ravi Amrit Madan - Laboratory of Tumor Immunology and Biology, National Cancer Institute at the National Institutes of Health
  BRD. D14 :   Prospective phase I/II trial of dose-painting prostate brachytherapy guided by cancer-specific ultrasound-based tissue-type imaging (TTI). (Abstract 246)
Presenting Author: Ronald D. Ennis - St. Luke's-Roosevelt and Beth Israel Medical Center, Continuum Cancer Centers of New York
  BRD. D15 :   Enzalutamide in men with prostate cancer resistant to docetaxel and abiraterone. (Abstract 247)
Presenting Author: Mark Creamer Scholz - Prostate Oncology Specialists
  BRD. D16 :   Looking to possible predictive factors of primary resistance to abiraterone acetate (AA) and enzalutamide (ENZ) in pretreated patients (pts) with castration-resistant prostate cancer (CRPC). (Abstract 248)
Presenting Author: Orazio Caffo - Santa Chiara Hospital
  BRD. D17 :   Consideration of height-based rather than weight-based dosing as a more appropriate method of treating with radium-223. (Abstract 249)
Presenting Author: Thomas Andrew Longo - University of Nebraska Medical Center
  BRD. D18 :   What is the optimal management of Gleason score 7 (GS7) prostate cancer (PC) at biopsy? A comparison of disease control for prostatectomy (RP) versus radiation therapy (RT). (Abstract 250)
Presenting Author: John Morgan Watkins - Bismarck Cancer Center
  BRD. D19 :   Interstitial fibrosis in radical prostatectomy specimen treated with neoadjuvant therapy and its relationship to biochemical outcome and castration-resistant status in high-risk prostate cancer. (Abstract 251)
Presenting Author: Yasuhiro Hashimoto - Department of Urology, Hirosaki University Graduate School of Medicine
  BRD. D20 :   The difference in implantation quality between loose seed and variable spacing strand seeds in the field of prostate brachytherapy. (Abstract 252)
Presenting Author: Pigné Grégoire - Hospices Civils de Lyon - Centre Hospitalier Lyon-Sud
  BRD. D21 :   Safety and clinical outcome of a cohort of patients (pts) with castration resistant prostate cancer (CRPC)  treated with abiraterone acetate (AA) in a named patient program (NPP): Updated results of a retrospective study from an Italian cooperative group. (Abstract 253)
Presenting Author: Orazio Caffo - Santa Chiara Hospital
  BRD. E1 :   Incidence of patient-reported urinary incontinence after stereotactic body radiation therapy for clinically localized prostate cancer. (Abstract 254)
Presenting Author: Leonard N. Chen - Georgetown University Medical Center
  BRD. E2 :   Prediction of prostate cancer Gleason score using a MRI-based nomogram. (Abstract 255)
Presenting Author: Mohummad Minhaj Siddiqui - Urologic Oncology Branch, National Cancer Institute at the National Institutes of Health
  BRD. E3 :   Characteristics and outcome of octogenarian versus young patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) treated with ketoconazole. (Abstract 256)
Presenting Author: Victoria J. Sinibaldi - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  BRD. E4 :   Efficacy of new agents on advanced castration-refractory prostate cancer with RAPID progression. (Abstract 257)
Presenting Author: Shenhong Wu - Northport Veterans Affairs Medical Center
  BRD. E5 :   Prospective evaluation of prescribing preferences (PPref) by U.S.-based oncologists in the postdocetaxel mCRPC patient. (Abstract 258)
Presenting Author: Charles J. Ryan - University of California, San Francisco
  BRD. E6 :   Oncologic outcomes of radical prostatectomy with neoadjuvant LHRH agonist/estramustine and radiotherapy with neoadjuvant hormonal therapy for high-risk prostate cancer. (Abstract 259)
Presenting Author: Takuya Koie - Department of Urology, Hirosaki University Graduate School of Medicine
  BRD. E7 :   Exosomal microRNA as prognostic biomarkers in metastatic castrate-resistant prostate cancer (mCRPC). (Abstract 260)
Presenting Author: Manish Kohli - Mayo Clinic
  BRD. E8 :   Surgical pathology and the patient: A systematic review evaluating the primary audience of pathology reports. (Abstract 261)
Presenting Author: Matthew Mossanen - University of Washington, School of Medicine
  BRD. E9 :   A sector-based postimplant dosimetric comparison of sagittal and axial ultrasound-guided source placement during I-125 permanent prostate brachytherapy. (Abstract 262)
Presenting Author: Ahamed Badusha Mohamed Yoosuf - Radiotherapy Medical Physics Section, Northern Ireland Cancer Centre
  BRD. E10 :   A phase I trial of muscadine grape skin in men with biochemically recurrent prostate cancer. (Abstract 263)
Presenting Author: Channing Judith Paller - Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins
  BRD. E11 :   Pilot study of focal salvage high-dose rate (HDR) prostate brachytherapy in patients with local recurrence after definitive external-beam radiotherapy (XRT). (Abstract 264)
Presenting Author: Hans T. Chung - Odette Cancer Centre, Sunnybrook Health Sciences Centre; University of Toronto
  BRD. E12 :   Real-world corticosteroid utilization in prostate cancer patients treated with two new oral agents. (Abstract 265)
Presenting Author: Marie-Helene Lafeuille - Groupe d'Analyse, Ltee
  BRD. E13 :   Expression of prostate-specific membrane antigen (PSMA) on circulating tumor cells (CTCs) in castration-resistant prostate cancer. (Abstract 266)
Presenting Author: Florence Lee - Epic Sciences, Inc.
  BRD. E14 :   Prostate cancer patients' adherence to medication while on abiraterone acetate (AA) therapy. (Abstract 267)
Presenting Author: Chris M. Kozma - CK Consulting
  BRD. E15 :   Presence of intraductal carcinoma of the prostate on needle biopsy as a prognostic factor for prostate cancer in radical prostatectomy patients. (Abstract 268)
Presenting Author: Masashi Kato - Department of Urology, Nagoya University Graduate School of Medicine
  BRD. E16 :   Novel dosimetric criteria for salvage permanent brachytherapy based on 3D-cancer mapping. (Abstract 269)
Presenting Author: Koji Okihara - Department of Urology, Kyoto Prefectural University of Medicine
  BRD. E17 :   An indirect treatment comparison (ITC) and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-chemotherapy. (Abstract 270)
Presenting Author: Tracy Li - Janssen Global Services
  BRD. E18 :   Standardizing patient-centered outcomes measurement in prostate cancer: An international, cross-disciplinary effort. (Abstract 271)
Presenting Author: Neil E. Martin - Department of Radiation Oncology, Brigham and Women’s Hospital/Dana-Farber Cancer Institute
  BRD. F1 :   Cytoreductive radical prostatectomy (CRP) in patients with prostate cancer (PCA) and low-volume osseous metastases. (Abstract 272)
Presenting Author: Axel Heidenreich - Department of Urology, RWTH University
  BRD. F2 :   The management of adenocarcinoma of the prostate in rural Georgia: A population-based analysis. (Abstract 273)
Presenting Author: William A. Hall - Department of Radiation Oncology and Winship Cancer Institute, Emory University
  BRD. F3 :   Allegheny General Hospital experience with LDR prostate brachytherapy comparing Pd-103 with I-125. (Abstract 274)
Presenting Author: Michael William Hall - Allegheny General Hospital
  BRD. F4 :   ODM-201 and the CNS: A clinical perspective.^ (Abstract 275)
Presenting Author: Neal D. Shore - Carolina Urologic Research Center, Atlantic Urology Clinics
  BRD. F5 :   The REQUITE project: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side effects. (Abstract 276)
Presenting Author: Tiziana Rancati - Fondazione IRCCS Istituto Nazionale dei Tumori
  BRD. F6 :   The effect of cell cycle progression (CCP) score on treatment decisions in prostate cancer: Results of an ongoing registry trial. (Abstract 277)
Presenting Author: Ashok J. Kar - St. Joseph Hospital
  BRD. F7 :   Quality of life after high-dose rate brachytherapy monotherapy for prostate cancer. (Abstract 278)
Presenting Author: Jessika Contreras - University of South Florida Morsani College of Medicine
  BRD. F8 :   Biochemical outcome of small volume or insignificant prostate cancer treated with radical prostatectomy. (Abstract 279)
Presenting Author: Yasuhiro Hashimoto - Department of Urology, Hirosaki University Graduate School of Medicine
  BRD. F9 :   Relationship of bone scan index and progression-free survival after docetaxel treatment for CRPC patients with bone metastases. (Abstract 280)
Presenting Author: Atsushi Mizokami - Kanazawa University Graduate School of Medical Science
  BRD. F10 :   In vitro efficacy of MAGMAS inhibition in prostate cancer. (Abstract 281)
Presenting Author: Boumediene Bouzahzah - Kansas University Medical Center
  BRD. F11 :   Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC). (Abstract 282)
Presenting Author: Antoine Angelergues - Department of Medical Oncology, Georges Pompidou European Hospital
  BRD. F12 :   The prevalence of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results from a single-institution experience. (Abstract 283)
Presenting Author: Amarnath Challapalli - Imperial College London
  BRD. F13 :   SUCCINCT: A phase II single-arm trial evaluating cisplatin and gemcitabine (CG) chemotherapy in combination with sunitinib (S) as first-line treatment of patients with advanced urothelial transitional cell carcinoma (TCC). (Abstract LBA289) (Abstract 283)
Presenting Author: Thomas R. Geldart - Royal Bournemouth Hospital
  BRD. F14 :   Frequent truncating mutations of the cohesin complex gene STAG2 in urothelial carcinoma of the bladder. (Abstract 290)
Presenting Author: David A. Solomon - University of California, San Francisco
  BRD. F15 :   Phase I dose-escalated image guided adaptive bladder radiotherapy study: Results of first dose cohort (68Gy). (Abstract 291)
Presenting Author: Robert Huddart - The Institue of Cancer Research, The Royal Marsden NHS Foundation Trust
  BRD. F16 :   Quality of transurethral resection in patients with bladder cancer: A process-outcomes link. (Abstract 292)
Presenting Author: Eric Ballon-Landa - UCLA Fielding School of Public Health
  BRD. F17 :   Branched evolution and intratumor heterogeneity of urothelial carcinoma of the bladder. (Abstract 293)
Presenting Author: Eugene K. Cha - Memorial Sloan-Kettering Cancer Center
  BRD. G1 :   Prerandomization factors and utilization of neoadjuvant chemotherapy in a clinical trial of extended versus standard pelvic lymphadenectomy at the time of radical cystectomy for bladder cancer. (Abstract 295)
Presenting Author: Seth P. Lerner - Baylor College of Medicine
  BRD. G2 :   NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters and safety in patients with surgically resected HER2+ urothelial cancer.^ (Abstract 296)
Presenting Author: Dean F. Bajorin - Memorial Sloan-Kettering Cancer Center
  BRD. G3 :   Optimizing a risk stratification for local-regional failure after radical cystectomy using the SWOG 8710 cohort. (Abstract 297)
Presenting Author: Brian C. Baumann - Department of Radiation Oncology, University of Pennsylvania
  BRD. G4 :   Multi-institutional quality care initiative (QCI) to improve the care of patients with invasive bladder cancer (BlCa). (Abstract 298)
Presenting Author: Bernard H. Bochner - Memorial Sloan-Kettering Cancer Center
  BRD. G5 :   Phase II trial of pazopanib and weekly paclitaxel in metastatic urothelial cancer (UC). (Abstract 299)
Presenting Author: Sandy Srinivas - Stanford Medical Center
  BRD. G6 :   BASE47 gene set predictor as an identifier of “basal-like” subtype of urothelial carcinoma of the bladder in African Americans. (Abstract 300)
Presenting Author: David D. Chism - UNC Lineberger Comprehensive Cancer Center
  BRD. G7 :   Peculiar study: Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer. (Abstract 301)
Presenting Author: Jae-Lyun Lee - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine
  BRD. G8 :   Geographic and racial disparities in the utilization of low-volume cystectomy hospitals for bladder cancer. (Abstract 302)
Presenting Author: Martin Francis Casey - Icahn School of Medicine at Mount Sinai
  BRD. G9 :   Treatment patterns in patients with recurrent high-risk bladder cancer. (Abstract 303)
Presenting Author: Eric Ballon-Landa - UCLA Fielding School of Public Health
  BRD. G10 :   Racial disparities in the morbidity of radical cystectomy in the United States. (Abstract 304)
Presenting Author: Tudor Borza - Division of Urology, Brigham and Women's Hospital
  BRD. G11 :   Phase II study of neoadjuvant sorafenib plus cisplatin and gemcitabine (S-CG) for patients with muscle-invasive transitional cell carcinoma of the bladder (MIBC): Results at the end of first stage (NCT01222676). (Abstract 305)
Presenting Author: Andrea Necchi - Fondazione IRCCS Istituto Nazionale dei Tumori
  BRD. G12 :   Neoadjuvant gemcitabine-cisplatin (GC) for muscle-invasive bladder cancer (MIBC): Does midway CT staging predict for pathologic complete response (pCR)? (Abstract 306)
Presenting Author: Jo-An Seah - Princess Margaret Cancer Centre, University Health Network, Division of Oncology and Haematology
  BRD. G13 :   A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC). (Abstract 307)
Presenting Author: Andrea Borghese Apolo - National Cancer Institute at the National Institutes of Health
  BRD. G14 :   Using exon-capture, deep sequencing of high-grade bladder urothelial carcinoma to identify recurrent genetic alterations and potential therapeutic targets. (Abstract 308)
Presenting Author: Philip H. Kim - Memorial Sloan-Kettering Cancer Center
  BRD. G15 :   Targeted sequencing of upper tract urothelial carcinoma. (Abstract 309)
Presenting Author: John P. Sfakianos - Memorial Sloan-Kettering Cancer Center
  BRD. G16 :   EAU and NCCN surveillance guidelines for bladder cancer: Do they effectively capture recurrences following cystectomy? (Abstract 310)
Presenting Author: Suzanne B. Stewart - Department of Urology, Mayo Clinic
  BRD. G17 :   Molecular profiling of infiltrating urothelial carcinoma of the bladder. (Abstract 311)
Presenting Author: Sherri Z. Millis - Caris Life Sciences
  BRD. G18 :   Outcomes in patients with p0 versus PCIS on final cystectomy pathology. (Abstract 312)
Presenting Author: Vishnukamal Golla - The University of Texas MD Anderson Cancer Center
  BRD. G19 :   Decreasing length of hospital stay following radical cystectomy using multimodal enhanced recovery protocol. (Abstract 313)
Presenting Author: Hooman Djaladat - USC Institute of Urology, University of Southern California
  BRD. G20 :   Changes in relative conditional survival (RCS) in de novo metastatic urothelial carcinoma (mUC): A Surveillance, Epidemiology, and End Results (SEER) database analysis. (Abstract 314)
Presenting Author: Sumanta Kumar Pal - City of Hope Comprehensive Cancer Center
  BRD. G21 :   NOTCH2 inhibition on tumor growth and metastasis in bladder cancer. (Abstract 315)
Presenting Author: Tetsutaro Hayashi - Vancouver Prostate Centre
  BRD. G22 :   The high incidence of vascular thromboembolic events (VTE) in advanced urothelial cancer (UC) patients (pts) treated with carboplatin (Cb): Analysis of treatment with gemcitabine (G)/cb (GCb), gcb/bevacizumab (GCbBev), or gemcitabine/cisplatin (GCis). (Abstract 316)
Presenting Author: Christopher Michael Tully - Memorial Sloan-Kettering Cancer Center
  BRD. H1 :   Changes in health-related quality of life (HRQL) after bladder cancer (BC) diagnosis (DX): A longitudinal population-based study. (Abstract 317)
Presenting Author: Chunkit Fung - James P. Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry
  BRD. H2 :   Outcome of patients with clinically node-positive bladder cancer who undergo consolidative surgery after preoperative chemotherapy: MD Anderson Cancer Center experience. (Abstract 318)
Presenting Author: Philip Levy Ho - The University of Texas MD Anderson Cancer Center
  BRD. H3 :   Quantification and molecular profiling of circulating tumor cells (CTCs) in urothelial cancer (UC) before and during systemic treatment: Implications across the clinical stages. (Abstract 319)
Presenting Author: Andrea Necchi - Fondazione IRCCS Istituto Nazionale dei Tumori
  BRD. H4 :   Concurrent cisplatin and radiotherapy: Decision making, tolerability, and outcomes for patients treated in a multidisciplinary bladder clinic. (Abstract 320)
Presenting Author: Nafisha Lalani - University of Toronto
  BRD. H5 :   Phase Ib/II trial of gemcitabine, cisplatin, plus lenalidomide as first-line therapy for patients with metastatic urothelial carcinoma. (Abstract 321)
Presenting Author: Che-Kai Tsao - The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
  BRD. H6 :   Efficacy of single-agent pemetrexed in platinum refractory metastatic urothelial cancer (mUC). (Abstract 322)
Presenting Author: David J. Benjamin - Tulane University School of Medicine
  BRD. H7 :   Multi-institutional evaluation of the prognostic significance of altered mammalian target of rapamycin (mTOR) pathway biomarkers in upper-tract urothelial carcinoma (UTUC). (Abstract 323)
Presenting Author: Aditya Bagrodia - The University of Texas Southwestern Medical Center
  BRD. H8 :   Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). (Abstract 324)
Presenting Author: Beatrice Knudsen - Cedars-Sinai Medical Center
  BRD. H9 :   Cancer-specific survival in patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy: External validation of the prognostic risk stratification model. (Abstract 325)
Presenting Author: Tohru Nakagawa - Department of Urology, Faculty of Medicine, The University of Tokyo
  BRD. H10 :   Neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) in patients with high-grade upper-tract urothelial carcinoma. (Abstract 326)
Presenting Author: Jean H. Hoffman-Censits - Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University
  BRD. H11 :   Clinical T1 urothelial bladder cancer: USC experience. (Abstract 327)
Presenting Author: Mehrdad Alemozaffar - USC Institute of Urology
  BRD. H12 :   Treatment target development in muscle-invasive bladder cancer. (Abstract 328)
Presenting Author: Mick D. Brown - Faculty Institute of Cancer Sciences
  BRD. H13 :   Assessment of bone metastases in patients (pts) with urothelial carcinoma using 18F-sodium fluoride PET/CT (18F-NaF) versus 18F-fluorodeoxyglucose PET/CT (18F-FDG). (Abstract 329)
Presenting Author: Benjamin Adam Weinberg - Georgetown University Hospital
  BRD. H14 :   Adjuvant chemotherapy for upper-tract urothelial carcinoma: A systematic review and meta-analysis of available studies. (Abstract 330)
Presenting Author: Jeffrey J. Leow - Brigham and Women's Hospital
  BRD. H15 :   The efficacy of EORTC risk tables in Japanese patients with non-muscle invasive bladder cancer. (Abstract 331)
Presenting Author: Satoru Muto - Teikyo Universirty
  BRD. H16 :   Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract (TCCU) after failure to one cisplatin-based systemic therapy in clinical practice. (Abstract 332)
Presenting Author: Belen Gonzalez-Grajera - Hospital Son Llatzer
  BRD. H17 :   Comparison of oncologic outcomes following systemic neoadjuvant chemotherapy and radical cystectomy in patients with mixed histologic variants and pure urothelial carcinoma of the bladder. (Abstract 333)
Presenting Author: Einar Freyr Sverrisson - Genitourinary Oncology Program, H. Lee Moffitt Cancer Center & Research Institute
  BRD. H18 :   Comparative effectiveness of radical cystectomy versus bladder-sparing treatment for muscle-invasive urothelial carcinoma: A population-based report. (Abstract 334)
Presenting Author: Maxine Sun - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center
  BRD. J1 :   Sources of variation in follow-up expenditure after radical cystectomy. (Abstract 335)
Presenting Author: Goutham Vemana - Washington University School of Medicine
  BRD. J2 :   Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy. (Abstract 336)
Presenting Author: Guru Sonpavde - University of Alabama, Birmingham (UAB) Comprehensive Cancer Center
  BRD. J3 :   Intravesical lipiodol injection technique for image-guided radiation therapy for bladder cancer. (Abstract 337)
Presenting Author: Adam S. Baumgarten - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute
  BRD. J4 :   Using microRNA (miRNA) profiling to differentiate noninvasive and muscle-invasive from metastases of transitional cell carcinoma of the urinary bladder (TCC-UB). (Abstract 338)
Presenting Author: Obiageli Uchenna Ogbata - The West Clinic
  BRD. J5 :   Venothromboembolism and radical cystectomy: Prevalence of risk factors and comparison of anticoagulation use. (Abstract 339)
Presenting Author: Andrew Sun - USC Institute of Urology
  BRD. J6 :   Radical cystectomy versus trimodality bladder-preserving therapy for muscle-invasive bladder cancer among elderly (80-84 years old) patients. (Abstract 340)
Presenting Author: Shingo Hatakeyama - Department of Urology, Hirosaki University Graduate School of Medicine
  BRD. J7 :   Predictive and prognostic significance of early positron emission tomography/computed tomography (PET/CT) in advanced transitional cell carcinoma. (Abstract 341)
Presenting Author: Patrizia Giannatempo - Fondazione IRCCS Istituto Nazionale dei Tumori
  BRD. J8 :   Clinical evaluation of cisplatin sensitivity germ line polymorphisms in neoadjuvant chemotherapy (NAC) for urothelial cancer (UC). (Abstract 342)
Presenting Author: Peter H. O'Donnell - The University of Chicago
  BRD. J9 :   Pilot investigation of variants in DNA repair pathways and association with response to platinum-based chemotherapy in bladder cancer. (Abstract 343)
Presenting Author: Ryan P. Kopp - Memorial Sloan-Kettering Cancer Center
  BRD. J10 :   C-reactive protein prior to cystectomy: An external validation of the TNR-C score. (Abstract 344)
Presenting Author: Mario W. Kramer - Medical School Hannover, Hannover, Germany; Department of Urology and Urologic Oncology
  BRD. J11 :   Time delays to radical cystectomy by use of neoadjuvant chemotherapy associated with higher rates of progression. (Abstract 345)
Presenting Author: William P. Parker - The University of Kansas Hospital
  BRD. J12 :   Association of care transitions with treatment delay for patients with muscle-invasive bladder cancer. (Abstract 346)
Presenting Author: Jeffrey J. Tomaszewski - Fox Chase Cancer Center
  BRD. J13 :   Assessment of bowel disorders following radial cystectomy and urinary diversion for muscle-invasive transitional cell carcinoma of the bladder. (Abstract 347)
Presenting Author: Mario W. Kramer - Medical School Hannover, Hannover, Germany; Department of Urology and Urologic Oncology
  BRD. J14 :   Trends in the utilization of diagnositics for upper-tract urothelial carcinoma. (Abstract 348)
Presenting Author: Goutham Vemana - Washington University School of Medicine
  BRD. J15 :   Heterogeneity of circulating tumor cells isolated from bladder cancer patients using ApoStream and biomarkers of epithelial-mesenchymal transition. (Abstract 349)
Presenting Author: Colin P. N. Dinney - The University of Texas MD Anderson Cancer Center
  BRD. J16 :   Impact of perivesical lymph nodes on survival after radical cystectomy. (Abstract 350)
Presenting Author: Brian Robin Hu - University of Southern California Institute of Urology
  BRD. K1 :   Evaluation of the neutrophil-lymphocyte ratio (NLR) during neoadjuvant chemotherapy (NC) for muscle-invasive bladder cancer (MIBC) and correlation with pathologic response to treatment. (Abstract 351)
Presenting Author: Jo-An Seah - Princess Margaret Cancer Centre, University Health Network, Division of Oncology and Haematology
  BRD. K2 :   Preoperative pitfalls: Prediction of pathologic lymph node status in patients undergoing neoadjuvant chemotherapy and radical cystectomy. (Abstract 352)
Presenting Author: Patrick Espiritu - Genitourinary Oncology Program, H. Lee Moffitt Cancer Center & Research Institute
  BRD. K3 :   Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy. (Abstract 353)
Presenting Author: Guru Sonpavde - US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX, and Deke Slayton Cancer Center
  BRD. K4 :   Response to second-line chemotherapy (Ctx) in advanced urothelial carcinoma: A pooled retrospective analysis of the correlation between objective response rate (ORR) and progression-free survival (PFS) and overall survival (OS). (Abstract 354)
Presenting Author: Anuradha Jayaram - Department of Medical Oncology Tallaght Hospital
  BRD. K5 :   Gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND) for patients (pts) with muscle-invasive bladder cancer (MIBC): Assessing impacts of neoadjuvant chemotherapy (NAC) and the PLND. (Abstract 355)
Presenting Author: Christopher Michael Tully - Memorial Sloan-Kettering Cancer Center
  BRD. K6 :   The significance of protocol biopsy after intravesical BCG treatment in patients with non-muscle–invasive bladder cancer. (Abstract 356)
Presenting Author: Satoru Maruyama - Department of Urology, Hokkaido University Graduate School of Medicine
  BRD. K7 :   Outcomes of radical cystectomy in potential candidates for bladder-preservation therapy. (Abstract 357)
Presenting Author: Eugene J. Pietzak - Department of Urology, Hospital of the University of Pennsylvania,
  BRD. K8 :   Somatic copy number abnormalities (SCNAs) and mutations in PI3K/AKT pathway and prognostic significance for overall survival (OS) in platinum-treated locally advanced or metastatic urothelial cancer (UC). (Abstract 358)
Presenting Author: Joaquim Bellmunt - Dana-Farber Cancer Institute
  BRD. K9 :   Vinflunine maintenance therapy versus best supportive care after platinum combination in advanced bladder cancer: A phase II, randomized, open label, study (MAJA study, SOGUG 2011-02)—Interim analysis on safety. (Abstract 359)
Presenting Author: Susana Hernando Polo - Hospital Universitario Fundación de Alcorcón
  BRD. K10 :   Development of a new outcome-prediction model for patients with urothelial carcinoma of the bladder prior to cystectomy. (Abstract 360)
Presenting Author: Mario W. Kramer - Medical School Hannover, Hannover, Germany; Department of Urology and Urologic Oncology
  BRD. K11 :   Using radiologic response to predict prognosis in patients with muscle-invasive bladder cancer undergoing carboplatin-based neoadjuvant chemotherapy. (Abstract 361)
Presenting Author: Shingo Hatakeyama - Department of Urology, Hirosaki University Graduate School of Medicine
  BRD. K12 :   Palonostron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) during gemcitabine/cisplatin (GC) in urothelial cancer (UC) patients: A multi-institutional retrospective study in Japan. (Abstract 362)
Presenting Author: Hiroshi Kitamura - School of Medicine, Sapporo Medical University
  BRD. K13 :   An audit of adjuvant carboplatin in patients with stage I testicular seminoma (Anglian Germ Cell Cancer Group, UK). (Abstract 366)
Presenting Author: Amy Kwan - Cambridge University Hospitals NHS Foundation Trust
  BRD. K14 :   Sorafenib monotherapy in patients with inoperable/recurrent germ cell tumors (GCT) refractory to chemotherapy: Phase II study. (Abstract 367)
Presenting Author: Iwona Anna Skoneczna - Institute of Oncology
  BRD. K15 :   Modern patterns of care in testicular seminoma: Results from the National Cancer database. (Abstract 368)
Presenting Author: Phillip John Gray - Harvard Radiation Oncology Program
  BRD. K16 :   United States trends in patterns of care in clinical stage I testicular cancer: Results from the National Cancer Database (1998-2011). (Abstract 369)
Presenting Author: Claudio Jeldres - Virginia Mason Medical Center
  BRD. K17 :   Trends of multimodal therapy in high-stage penile cancer. (Abstract 370)
Presenting Author: Elizabeth Kate Ferry - Case Western Reserve University/University Hospitals Urology Institute
  BRD. K18 :   Complications during cisplatin-based primary chemotherapy in patients with testicular cancer: Is there a need for thromboembolic prophylaxis? (Abstract 371)
Presenting Author: David J. K. P. Pfister - RWTH University Aachen
  BRD. K19 :   The impact of clinical trial evidence and sociodemographic factors on institutional practice patterns for stage I testicular cancer. (Abstract 372)
Presenting Author: Gautum Agarwal - Genitourinary Oncology Program, H. Lee Moffitt Cancer Center & Research Institute
  BRD. K20 :   Enhancing risk stratification in primary mediastinal nonseminomatous germ cell tumors (PMNSGCT): A 27-year experience at a tertiary cancer center. (Abstract 373)
Presenting Author: Andrea Necchi - Fondazione IRCCS Istituto Nazionale dei Tumori
  BRD. K21 :   Dose calculation and tolerability of adjuvant AUC 7 carboplatin in 100 patients with stage I seminoma. (Abstract 374)
Presenting Author: Umberto Basso - Istituto Oncologico Veneto-IOV-I.R.C.C.S.
  BRD. K22 :   Thromboembolic events (TE) in men treated with bleomycine-etoposide-cisplatin (BEP): A monocentric review over one year. (Abstract 375)
Presenting Author: Helen Jane Boyle - Centre Léon Bérard
  BRD. L1 :   Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial. (Abstract 376)
Presenting Author: Patrizia Giannatempo - Fondazione IRCCS Istituto Nazionale dei Tumori
  BRD. L2 :   Survival analyses of adjuvant or neoadjuvant combination of a taxane plus cisplatin and 5-fluorouracil (T-PF) in patients with bulky nodal metastases from squamous cell carcinoma of the penis (PSCC): Results of a single high-volume center. (Abstract 377)
Presenting Author: Patrizia Giannatempo - Fondazione IRCCS Istituto Nazionale dei Tumori
  BRD. L3 :   Do seminoma germ cell elements affect perioperative outcomes following post-chemotherapy retroperitoneal lymph node dissection for metastatic testis cancer? (Abstract 378)
Presenting Author: Gautum Agarwal - Genitourinary Oncology Program, H. Lee Moffitt Cancer Center & Research Institute
  BRD. L4 :   Surgical management trends of penile cancer in the United States between 2000 and 2010. (Abstract 379)
Presenting Author: Elizabeth Kate Ferry - Case Western Reserve University/University Hospitals Urology Institute
  BRD. L5 :   Stage I testicular tumor: How frequently to scan? (Abstract 380)
Presenting Author: Sindhu Ramamurthy - Northern Centre for Cancer Care, Freeman Hospital
  BRD. L6 :   To what degree is there interobserver variability among pathologists for T1 penile cancer? (Abstract 381)
Presenting Author: Adam Luchey - Genitourinary Oncology Program, H. Lee Moffitt Cancer Center & Research Institute
  BRD. L7 :   Vascular anomalies in patients undergoing retroperitoneal lymph node dissection. (Abstract 382)
Presenting Author: Andrea K. Thissen - RWTH University Aachen
  BRD. L8 :   Integrated comprehensive high-throughput kinomics profiling and whole exome sequencing of penile squamous cell cancer (PSCC). (Abstract 383)
Presenting Author: Amitkumar N. Mehta - University of Alabama at Birmingham
  BRD. L9 :   Impact of extrascrotal symptoms on treatment outcome in patients with nonseminomatous germ cell tumor with intermediate or poor prognosis. (Abstract 384)
Presenting Author: Shigeyuki Yamada - Department of Urology, Tohoku University Graduate School of Medicine
  BRD. L10 :   Management of growing teratoma syndrome: Aachen University experience. (Abstract 385)
Presenting Author: David J. K. P. Pfister - RWTH University Aachen
  BRD. L11 :   Inguinal lymph node dissection for penile cancer: Predictors of lymph node metastasis. (Abstract 386)
Presenting Author: Adam Luchey - Genitourinary Oncology Program, H. Lee Moffitt Cancer Center & Research Institute
  BRD. M1 :   Surgical management of testicular cancer patients with complex postchemotherapy residual masses: Aachen University experience. (Abstract 387)
Presenting Author: Axel Heidenreich - Department of Urology, RWTH University
  BRD. M2 :   Utilization of adjuvant therapy in Medicaid and uninsured seminoma patients: Results from the National Cancer Database. (Abstract 388)
Presenting Author: Jonathan J. Paly - Massachusetts General Hospital
  BRD. M3 :   Clinical characteristics and outcomes of patients with primary mediastinal germ cell tumors. (Abstract 389)
Presenting Author: Siwat Sakdejayont - Department of Internal Medicine, Prince of Songkla University
  BRD. M4 :   Nonseminomatous germ cell tumor of the testis: Prognostic factors for a lethal phenotype. (Abstract 390)
Presenting Author: Shi-Ming Tu - The University of Texas MD Anderson Cancer Center
  BRD. M5 :   Influence of social demographics and African-American race on outcomes in testicular cancer: Analysis of 75,902 patients in the National Cancer database. (Abstract 391)
Presenting Author: Craig R. Nichols - Virginia Mason Medical Center

General Poster Session C: Renal Cell Cancer


  BRD. B1 :   ASET study: Long-term follow-up data of patients with metastatic renal cell carcinoma treated with MGN1601. (Abstract LBA399)
Presenting Author: Viktor Gruenwald - Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School
  BRD. B2 :   Results of a phase II trial of novel carbonic anhydrase IX radiotracer 18F-VM4-037 in renal cell carcinoma. (Abstract LBA400)
Presenting Author: Adam R. Metwalli - Urologic Oncology Branch, National Cancer Institute at the National Institutes of Health
  BRD. B3 :   Impact of follow-up imaging on overall and cancer specific survival after radical and partial nephrectomy. (Abstract 401)
Presenting Author: Seth A. Strope - Washington University School of Medicine
  BRD. B4 :   AUA and NCCN surveillance guidelines for RCC: Do they effectively capture recurrences following nephrectomy? (Abstract 402)
Presenting Author: Suzanne B. Stewart - Department of Urology, Mayo Clinic
  BRD. B5 :   Understanding treatment disconnect and mortality trends in renal cell carcinoma using tumor registry data. (Abstract 403)
Presenting Author: Marc C. Smaldone - Fox Chase Cancer Center
  BRD. B6 :   Professional practice gaps and barriers to optimal care of renal cell carcinoma (RCC) among oncologists in the United States. (Abstract 404)
Presenting Author: Brian I. Rini - Cleveland Clinic, Taussig Cancer Institute
  BRD. B7 :   Development and validation of a prognostic nomogram for progression-free and overall survival in patients with advanced renal cell carcinoma (aRCC) treated with pazopanib. (Abstract 405)
Presenting Author: Michael W. Kattan - Quantitative Health Sciences, Cleveland Clinic
  BRD. B8 :   Results of a feasibility study of I-124 girentuximab in metastatic clear cell renal cell carcinoma (m ccRCC). (Abstract 406)
Presenting Author: Stephen Michael Keefe - Abramson Cancer Center of the University of Pennsylvania
  BRD. B9 :   c-Met abnormatities in patients with genitourinary (GU) malignancies and outcomes with c-MET inhibitors. (Abstract 407)
Presenting Author: Denis Leonardo Fontes Jardim - The University of Texas MD Anderson Cancer Center
  BRD. B10 :   The effect of sunitinib on biomarkers and tumour heterogeneity in metastatic clear cell renal cancer. (Abstract 408)
Presenting Author: Grant Stewart - University of Edinburgh
  BRD. B11 :   Comprehensive kinase profiling to classify clear cell (cc)-renal cell carcinoma (RCC). (Abstract 409)
Presenting Author: Amitkumar N. Mehta - University of Alabama at Birmingham
  BRD. B12 :   Open-label, phase II raptor study of everolimus (EVE) for papillary mRCC: Efficacy in type 1 and type 2 histology. (Abstract 410)
Presenting Author: Bernard J. Escudier - Institut Gustave Roussy
  BRD. B13 :   Deep sequencing of sarcomatoid renal cell carcinoma (sRCC) and identification of aurora kinases and mTOR as potential therapeutic targets. (Abstract 411)
Presenting Author: Sumanta Kumar Pal - City of Hope
  BRD. B14 :   Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC). (Abstract 412)
Presenting Author: Stephen Michael Keefe - Abramson Cancer Center of the University of Pennsylvania
  BRD. B15 :   Identification of quality improvement opportunities in kidney cancer surgery through a regional hospital-based urologic quality collaborative. (Abstract 413)
Presenting Author: John L. Gore - University of Washington, School of Medicine
  BRD. B16 :   Loss of BAP1 and PBRM1 protein expression and its association with clear cell renal cell carcinoma-specific survival. (Abstract 414)
Presenting Author: Richard Wayne Joseph - Mayo Clinic Cancer Center
  BRD. B17 :   Safety and efficacy of addition of VEGFR and EGFR-family small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: A meta-analysis. (Abstract 415)
Presenting Author: Tomohiro Funakoshi - Beth Israel Medical Center
  BRD. B18 :   Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis. (Abstract 416)
Presenting Author: Toni K. Choueiri - Dana-Farber Cancer Institute
  BRD. B19 :   Survival outcomes associated with different sunitinib dosing regimens in metastatic renal cell carcinoma. (Abstract 417)
Presenting Author: Winnie Cheng - BC Cancer Agency
  BRD. B20 :   Correlation between patient-reported fatigue and hemoglobin (Hgb) levels in metastatic renal cell carcinoma (mRCC) patients (pts) receiving sunitinib (SU). (Abstract 418)
Presenting Author: Mellar P. Davis - Cleveland Clinic
  BRD. B21 :   Utility of 2-(18F) fluoro-2 deoxy-d-glucose PET/CT in advanced papillary renal cell carcinoma. (Abstract 419)
Presenting Author: Brian Shuch - Department of Urology, Yale University
  BRD. B22 :   Positive surgical margins after partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer Information System database. (Abstract 420)
Presenting Author: Rahul K. Bansal - McMaster Institute of Urology, St. Joseph's Hospital
  BRD. C1 :   SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). (Abstract 393)
Presenting Author: Maurice Stephan Michel - Department of Urology, University Medical Center Mannheim, University of Heidelberg
  BRD. C2 :   Results of the MARS study on the management of antiangiogenics’ renovascular safety in renal cell carcinoma. (Abstract 394)
Presenting Author: Isabelle Laure Ray-Coquard - Centre Léon Bérard
  BRD. C3 :   Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. (Abstract 395)
Presenting Author: A. Ari Hakimi Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center
  BRD. C4 :   Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (Abstract 396)
Presenting Author: Daniel Yick Chin Heng - Tom Baker Cancer Center, University of Calgary
  BRD. C5 :   Lymphopenia as an independent predictor of survival in papillary renal cell carcinoma. (Abstract 397)
Presenting Author: Reza Mehrazin - Fox Chase Cancer Center
  BRD. C6 :   The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT). (Abstract 398)
Presenting Author: Jenny J. Ko - Tom Baker Cancer Centre
  BRD. C7 :   Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma. (Abstract 421)
Presenting Author: Matteo Santoni - Medical Oncology, Polytechnic University of the Marche Region, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I-GM Lancisi and G Salesi
  BRD. C8 :   Risk of renal cell cancer in people immunodepressed after solid organ transplant: Results from an Italian multicenter cohort study. (Abstract 422)
Presenting Author: Pierluca Piselli - Department of Epidemiology, INMI “L. Spallanzani”
  BRD. C9 :   Postoperative complications of radical nephrectomy with atrial thrombectomy: A contemporary population-based analysis. (Abstract 423)
Presenting Author: Tudor Borza - Division of Urology, Brigham and Women's Hospital
  BRD. C10 :   PD-L1 expression in non-clear cell renal cell carcinoma. (Abstract 424)
Presenting Author: André P Fay - Dana-Farber Cancer Institute
  BRD. C11 :   Response to systemic therapy in non-clear cell renal cell carcinomas: A systematic review and meta-analysis. (Abstract 425)
Presenting Author: Francisco Emilio Vera-Badillo - Princess Margaret Cancer Centre - University Health Network; Department of Medicine, University of Toronto
  BRD. C12 :   Active surveillance as a treatment option for metastatic or recurrent renal cell carcinoma. (Abstract 426)
Presenting Author: Inkeun Park - Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Hospital
  BRD. C13 :   Phase II clinical trial of bevacizumab plus ixabepilone in renal cell carcinoma. (Abstract 427)
Presenting Author: Mauricio Emmanuel Burotto Pichun - National Cancer Institute at the National Institutes of Health
  BRD. C14 :   Circulating biomarkers and outcomes in a single-arm phase II trial of first-line sunitinib alternating with everolimus for advanced renal cell carcinoma (aRCC): EVERSUN ANZUP trial 0901. (Abstract 428)
Presenting Author: Sonia Yip - Sydney Catalyst Translational Cancer Research Centre
  BRD. D1 :   Interpreting first-line options in mRCC: A look into the German RCC-registry. (Abstract 429)
Presenting Author: Peter J. Goebell - Department of Urology, University Hospital Erlangen
  BRD. D2 :   High-dose interleukin-2 registry, PROCLAIM: Modern data on toxicities and outcomes. (Abstract 430)
Presenting Author: James N Lowder - Prometheus Labs
  BRD. D3 :   A single-arm, phase II, multicenter trial of sunitinib maleate (SU) in locally advanced or metastatic pheochromocytoma/paraganglioma (PC/PG): Interim results. (Abstract 431)
Presenting Author: Raya Leibowitz-Amit - Princess Margaret Cancer Centre - University Health Network; Department of Medicine, University of Toronto
  BRD. D4 :   Integrated analysis of metastatic disease in clear cell renal cell carcinoma: A collaborative TCGA analysis. (Abstract 432)
Presenting Author: A. Ari Hakimi - Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center
  BRD. D5 :   Phase I trial of sunitinib (S) and temsirolimus (T) in metastatic renal cell carcinoma (mRCC). (Abstract 433)
Presenting Author: Matthew T. Campbell - The University of Texas MD Anderson Cancer Center
  BRD. D6 :   Contemporary outcomes of pT3 renal cell carcinoma: A Canadian multi-institutional experience. (Abstract 434)
Presenting Author: Jasmir Nayak - University of Manitoba
  BRD. D7 :   The role of obesity in the incidence of lymphatic spread, disease-free, and overall survival: Data from the ARISER clinical trial. (Abstract 435)
Presenting Author: Karim Chamie - Department of Urology, University of California, Los Angeles
  BRD. D8 :   Surgeons’ preferences and practice patterns regarding intra-operative frozen section during partial nephrectomy. (Abstract 436)
Presenting Author: Abhinav Sidana - University Hosp, Cincinnati
  BRD. D9 :   Impact of angiotensin system inhibitors (ASI) on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database. (Abstract 437)
Presenting Author: Rana R. McKay - Dana-Farber Cancer Institute
  BRD. D10 :   EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901). (Abstract 438)
Presenting Author: Ian D. Davis - Monash University Eastern Health Clinical School
  BRD. D11 :   Association between clinical response and toxicities with drug exposure in an alternative dosing regimen of sunitinib. (Abstract 439)
Presenting Author: Ravindran Kanesvaran - National Cancer Centre Singapore
  BRD. D12 :   Growth kinetics and outcomes of cT1b renal masses under active surveillance. (Abstract 440)
Presenting Author: Reza Mehrazin - Fox Chase Cancer Center
  BRD. D13 :   Phase II trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.^ (Abstract 441)
Presenting Author: Jose A. Karam - The University of Texas MD Anderson Cancer Center
  BRD. D14 :   Examining the use of cell cycle progression score as a predictor of metastatic progression of clear cell renal cell carcinoma after resection. (Abstract 442)
Presenting Author: Eric J. Askeland - University of Iowa
  BRD. D15 :   Dovitinib in first-line renal cell carcinoma: An investigation into tumour gene status and correlation with efficacy: A phase II clinical trial. (Abstract 443)
Presenting Author: Reuben James Broom - Auckland City Hospital
  BRD. D16 :   Does nonsurgical management for localized kidney cancer equate to active surveillance in the SEER-Medicare population? (Abstract 444)
Presenting Author: Marc C. Smaldone - Fox Chase Cancer Center
  BRD. D17 :   Active surveillance of pulmonary metastases in renal cancer patients. (Abstract 445)
Presenting Author: Rozana Abdul Rahman - Department of Medical Oncology, Adelaide and Meath Hospital, incorporating the National Children's Hospital
  BRD. D18 :   Heterogeneity of intermediate prognosis patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib. (Abstract 446)
Presenting Author: Avishay Sella - Assaf Harofeh Medical Center
  BRD. D19 :   Disrcimination between Von Hippel-Lindau gene and hypoxia-regulated alterations in the metabolism and protein expression in renal cell carcinoma using ome-based strategies. (Abstract 447)
Presenting Author: Barbara Seliger - Department for Medical Immunology, Martin Luther University of Halle-Wittenberg
  BRD. D20 :   Prognostic value of flare-up phenomenon after discontinuation of sunitinib (SU) or pazopanib (PA) in metastatic renal cell carcinoma (mRCC). (Abstract 448)
Presenting Author: Roberto Iacovelli - Department of Medical Oncology, Institut Gustave Roussy
  BRD. D21 :   ADAPT:  An ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in advanced renal cell carcinoma (RCC).^ (Abstract 449)
Presenting Author: Robert A. Figlin - Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
  BRD. E1 :   Phase I study of pazopanib in combination with interferon alfa in patients with advanced renal cell carcinoma (RCC) and other primary tumors: A Spanish Oncology Genitourinary Group (SOGUG) study. (Abstract 450)
Presenting Author: Xavier Garcia del Muro - Institut Català d'Oncologia
  BRD. E2 :   Using biologic knowledge to discover molecular correlations between human renal cell carcinoma pathways. (Abstract 451)
Presenting Author: Vanessa Medina Villaamil - Biomedical Research Institute
  BRD. E3 :   Impact on clinical prognosis using DNA methylation of the SLC16A3 promoter and expression of the human lactate transporter MCT4 in renal cancer. (Abstract 452)
Presenting Author: Jens Bedke - Department of Urology, University Tuebingen
  BRD. E4 :   Src pathway activation in RCC and the correlation with grade and survival and the development of a rational new target in RCC. (Abstract 453)
Presenting Author: Chung-Han Lee - Memorial Sloan-Kettering Cancer Center
  BRD. E5 :   Validation of the CAIX score as a prognostic biomarker for lymphatic spread and cancer-specific survival. (Abstract 454)
Presenting Author: Karim Chamie - Department of Urology, University of California, Los Angeles
  BRD. E6 :   Multicenter phase II clinical trial of everolimus in Japanese patients with unresectable or metastatic renal cell carcinoma (mRCC) after failure of treatment with first-line tyrosine kinase inhibitor (TKI) therapy. (Abstract 455)
Presenting Author: Seiichiro Ozono - Department of Urology, Hamamatsu University School of Medicine
  BRD. E7 :   Outcomes of patients (pts) with metastatic non-clear-cell renal cell carcinoma (nccRCC) treated with pazopanib. (Abstract 456)
Presenting Author: Marc Ryan Matrana - Ochsner Medical Center
  BRD. E8 :   Treatment (tx) patterns and drug (Rx) costs for patients (pts) with metastatic renal cell carcinoma (mRCC) in the United States. (Abstract 457)
Presenting Author: Daniel M. Geynisman - Fox Chase Cancer Center, Temple University Health System
  BRD. E9 :   Assessing the significance of preoperative butyrylcholinesterase as an independent predictor of overall survival in patients with renal clear cell carcinoma treated with nephrectomy. (Abstract 458)
Presenting Author: Takuya Koie - Department of Urology, Hirosaki University Graduate School of Medicine
  BRD. E10 :   Using DNA hypermethylation biomarkers to predict therapy response of antiangiogenic therapy in metastatic renal cell carcinoma patients. (Abstract 459)
Presenting Author: Inga Peters - Medical School Hannover, Hannover, Germany; Department of Urology and Urologic Oncology
  BRD. E11 :   Conditional survival (CS) of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2). (Abstract 460)
Presenting Author: Kinjal Parikh - University of Utah, Huntsman Cancer Institute
  BRD. E12 :   Examining the clinical benefit (CB) of high-dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC). (Abstract 461)
Presenting Author: Neeraj Agarwal - University of Utah, Huntsman Cancer Institute
  BRD. E13 :   Long-term responders to everolimus: A subgroup analysis of the sector study. (Abstract 462)
Presenting Author: Philippe Barthelemy - Hôpitaux Universitaires de Strasbourg
  BRD. E14 :   A study of real-time CLIA-enabled whole genome tumor sequencing: Results for testicular cancer and sarcomatoid RCC. (Abstract 463)
Presenting Author: Alan Haruo Bryce - Mayo Clinic
  BRD. E15 :   Genome-wide profiling of histone 3 lysine 36 trimethylation in clear cell renal cell carcinoma. (Abstract 464)
Presenting Author: Thai Huu Ho - Mayo Clinic
  BRD. E16 :   Impact of altered Wnt1/ß-catenin expression on clinicopathology and prognosis in renal cell carcinoma. (Abstract 465)
Presenting Author: Stephan Kruck - Department of Urology, University Tuebingen
  BRD. E17 :   In vitro and in vivo effects of the mTOR inhibitors everolimus (EVE) and temsirolimus (TEM). (Abstract 466)
Presenting Author: David Chen - Novartis Pharmaceuticals Corporation
  BRD. E18 :   PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases. (Abstract 467)
Presenting Author: Marcella Callea - Brigham and Women's Hospital
  BRD. F1 :   Searching for circulating microRNAs in genitourinary tumors. (Abstract 468)
Presenting Author: Vanessa Medina Villaamil - Biomedical Research Institute
  BRD. F2 :   Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study. (Abstract 469)
Presenting Author: Peter J. Goebell - Department of Urology, Friedrich-Alexander University Erlangen
  BRD. F3 :   Neutrophil to lymphocyte ratio (NLR) and its effect on the prognostic value of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model for patients treated with targeted therapy (TT). (Abstract 470)
Presenting Author: Arnoud J. Templeton - Division of Medical Oncology, Princess Margaret Cancer Centre
  BRD. F4 :   Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study. (Abstract 471)
Presenting Author: Sergio Bracarda - Ospedale San Donato USL8, Istituto Toscano Tumori (ITT)
  BRD. F5 :   Trends in cytoreductive nephrectomy in the eras of immuno and targeted therapy. (Abstract 472)
Presenting Author: Brian J. Minnillo - Urological Institute, University Hospitals Case Medical Center, Case Western Reserve University
  BRD. F6 :   Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway–targeted therapy and one prior mTOR inhibitor therapy. (Abstract 473)
Presenting Author: Bernard J. Escudier - Institut Gustave Roussy
  BRD. F7 :   Correlation of distinctive angiogenetic profiles with clinical outcome for different treatment sequences in mRCC. (Abstract 474)
Presenting Author: Maristella Bianconi - Department of Medical Oncology - Università Politecnica delle Marche
  BRD. F8 :   Sterotactic body radiosurgery for primary small renal tumors: A retrospective analysis. (Abstract 475)
Presenting Author: Irving D. Kaplan - Beth Israel Deaconess Medical Center
  BRD. F9 :   Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). (Abstract 476)
Presenting Author: David D. Stenehjem - Pharmacotherapy Outcomes Research Center, College of Pharmacy, University of Utah
  BRD. F10 :   Neutrophil to lymphocyte ratio and response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma. (Abstract 477)
Presenting Author: Arnoud J. Templeton - Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre
  BRD. F11 :   Preclinical activity of the heat shock protein 90 inhibitor ganetespib in clear cell renal cell carcinoma. (Abstract 478)
Presenting Author: Mansi Parasramka - Mayo Clinic
  BRD. F12 :   Pharmacist-led monitoring program for patients on sunitinib for metastatic renal-cell carcinoma: A Canadian experience. (Abstract 479)
Presenting Author: Scott Edwards - Dr H. Bliss Murphy Cancer Center
  BRD. F13 :   Suitability of clear cell renal cell carcinoma to heat shock proteins-inhibitors. (Abstract 480)
Presenting Author: Matteo Brunelli - Department of Pathology and Diagnostic, Azienda Ospedaliera Universitaria Integrata (AOUI) and University of Verona, Italy
  BRD. F14 :   Circulating tumor cell kinetics in mRCC patients treated with sunitinib. (Abstract 481)
Presenting Author: Kriti Mittal - Cleveland Clinic
  BRD. F15 :   Bilateral multifocal papillary type I renal cell carcinoma: Clinical characteristics and association with chronic renal insufficiency. (Abstract 482)
Presenting Author: Daniel Su - Urologic Oncology Branch, National Cancer Institute at the National Institutes of Health
  BRD. F16 :   Immunohistochemical evaluation of aldose reductase expression in collecting duct carcinoma for differential diagnosis from other renal malignancy. (Abstract 483)
Presenting Author: Yasuhiro Hashimoto - Department of Urology, Hirosaki University Graduate School of Medicine
  BRD. F17 :   Association of partial nephrectomy and presence of robotic surgery for kidney cancer in the United States. (Abstract 484)
Presenting Author: Steven V. Kardos - Department of Urology, Yale University
  BRD. F18 :   Brain metastasis from renal cell carcinoma: Are we missing our chance to treat? (Abstract 485)
Presenting Author: Michael Hanzly - Roswell Park Cancer Institute
  BRD. G1 :   Patients with metastatic papillary renal cell carcinoma (RCC) who may benefit from sunitinib therapy (tx): Results from an international metastatic RCC database. (Abstract 486)
Presenting Author: Daniel Kejzman - Genitourinary Oncology Service, Division of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University
  BRD. G2 :   Association between rigors and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2). (Abstract 487)
Presenting Author: Julia Anne Batten - University of Utah, Huntsman Cancer Institute
  BRD. G3 :   The regulation of clear cell renal cancer cells proliferation and tyrosine kinase inhibitors responsiveness by tumor micro-environmental factors. (Abstract 488)
Presenting Author: Anna Malgorzata Czarnecka - Department of Oncology, Military Institute of Medicine
  BRD. G4 :   Salivary markers in renal cell carcinoma. (Abstract 489)
Presenting Author: Alexandra Dudek - Guy's and St Thomas' NHS Foundation Trust
  BRD. G5 :   A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells (DC) transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC. (Abstract 490)
Presenting Author: Fairooz F. Kabbinavar - Institute of Urologic Oncology, David Geffen School of Medicine at the University of California, Los Angeles
  BRD. G6 :   A weighted-adjusted indirect comparison of everolimus (EVE) versus axitinib (AXI) in second-line metastatic renal cell carcinoma (mRCC) patients who previously failed sunitinib therapy. (Abstract 491)
Presenting Author: Steven A. Sherman - Laser Analtyica
  BRD. G7 :   Second-line prescribing preferences (PPrefs) of U.S.-based medical oncologists’ (MOs) following first-line TKI in patients with metastatic clear cell renal cell carcinoma (mccRCC). (Abstract 492)
Presenting Author: Charles J. Ryan - University of California, San Francisco
  BRD. G8 :   Dysregulation of the beta-catenin complex as an independent predictor of oncological outcomes in patients with CCRCC. (Abstract 493)
Presenting Author: Laura-Maria Krabbe - The University of Texas Southwestern Medical Center
  BRD. G9 :   Potential impact of prior high-dose IL-2 on the outcomes of sunitinib (Su) treatment (tx) in patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract 494)
Presenting Author: Eli Rosenbaum - Rabin Medical Center
  BRD. G10 :   Results from a phase 2 trial of bortezomib (B) and sorafenib (S) in unresectable or metastatic renal cell cancer. (Abstract 495)
Presenting Author: Richard C. Lauer - University of New Mexico Cancer Center
  BRD. G11 :   MRC SORCE trial: Analysis of patients' presenting characteristics, tumor staging, and surgical approach. (Abstract 496)
Presenting Author: Alastair W.S. Ritchie - MRC Clinical Trials Unit at UCL Aviation House
  BRD. G12 :   Safety and efficacy of targeted therapy for renal cell carcinoma (RCC) with brain metastasis. (Abstract 497)
Presenting Author: Diogo Assed Bastos - Memorial Sloan-Kettering Cancer Center
  BRD. G13 :   Perioperative outcomes following surgical resection of renal cell carcinoma with upper level IVC thrombus: A contemporary multicenter experience. (Abstract 498)
Presenting Author: Edwin Jason Abel - University of Wisconsin School of Medicine and Public Health
  BRD. G14 :   Sequential treatment of advanced or metastatic renal cell carcinoma (mRCC): What is effective? Data from the German RCC registry. (Abstract 499)
Presenting Author: Lothar Mueller - Oncologie Leer - Emden
  BRD. G15 :   Acquired hypothyroidism as a predictive marker of outcome in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine-kinase inhibitors (TKIs): A literature-based meta-analysis. (Abstract 500)
Presenting Author: Andreas Demetrios Nearchou - Onkologkliniken Sörmland Mälarsjukhuset
  BRD. G16 :   Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat. (Abstract 501)
Presenting Author: Elizabeth R. Plimack - Fox Chase Cancer Center
  BRD. G17 :   Sunitinib versus sorafenib as first-line therapy for patients with metastatic renal cell carcinoma with favorable or intermediate MSKCC risk factors: A multicenter randomized trial, CROSS-J-RCC. (Abstract 502)
Presenting Author: Yoshihiko Tomita - Department of Urology, Yamagata University School of Medicine
  BRD. G18 :   Temporal trends and factors associated with receipt of systemic therapy among patients undergoing cytoreductive nephrectomy. (Abstract 503)
Presenting Author: Marc C. Smaldone - Fox Chase Cancer Center
  BRD. G19 :   Epidemiology and outcome of sarcomatoid renal cell cancer compared to clear cell renal cancer:  A Surveillance, Epidemiology, and End Results (SEER) database review. (Abstract 504)
Presenting Author: Mohammed Nawaf Kanaan - University of Arizona
  BRD. G20 :   U.S. regional practice patterns in metastatic renal cell carcinoma (mRCC) patients: A real-world retrospective analysis. (Abstract 505)
Presenting Author: Sumanta Kumar Pal - City of Hope
  BRD. G21 :   Are regional funding decisions resticting pharmaceutical research and development in metastatic renal cell carcinoma (mRCC)? (Abstract 506)
Presenting Author: Henry Jacob Conter - University of Western Ontario
  BRD. G22 :   Utilizing percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. (Abstract 507)
Presenting Author: Timothy Kim - Genitourinary Oncology Program, H. Lee Moffitt Cancer Center & Research Institute
  BRD. H1 :   Clinicopathologic factors associated with the development of sunitinib induced hypertension (HTN) in patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract 508)
Presenting Author: Victoria Neiman - Department of Oncology Rabin Medical Center
  BRD. H2 :   Retrospective evaluation of tyrosine kinase inhibitor (TKI)-everolimus (eve) and/or TKI-eve-TKI sequences in metastatic renal cell carcinoma (mRCC): A French survey—The sector study. (Abstract 509)
Presenting Author: Stephane Oudard - HEGP, Oncologie Médicale
  BRD. H3 :   Glandular metastasis as a surrogate for long survivors in metastatic renal carcinoma. (Abstract 510)
Presenting Author: Brice Chanez - Institut Paoli Calmettes
  BRD. H4 :   Survival of patients with papillary type II renal cell carcinoma treated with tyrosine-kinase inhibitors: A comparison with clear cell histologies. (Abstract 511)
Presenting Author: Jozefina Casuscelli - Department of Urology, University Hospital Munich-Grosshadern, Ludwig Maximilian University
  BRD. H5 :   Renal nephrometry score and predictors of complications in partial nephrectomies. (Abstract 512)
Presenting Author: Deepak K. Pruthi - University of Manitoba
  BRD. H6 :   The evolution of debulking nephrectomy and patient characteristics in metastatic renal cell cancer patients enrolled into first-line tyrosine kinase inhibitors clinical trials. (Abstract 513)
Presenting Author: Avishay Sella - Assaf Harofeh Medical Center
  BRD. H7 :   Reliability of the CT-SCAN percutaneous biopsy for small renal masses. (Abstract 514)
Presenting Author: Alexandre Ingels - Institut Mutualiste Montsouris
  BRD. H8 :   Association of baseline health and gender with small renal mass pathology. (Abstract 515)
Presenting Author: Wassim Bazzi - Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center
  BRD. H9 :   Diabetes mellitus and risk of cancer-specific mortality among patients with clear cell renal cell carcinoma undergoing nephrectomy. (Abstract 516)
Presenting Author: Sarah P. Psutka - Department of Urology, Mayo Clinic
  BRD. H10 :   Time from nephrectomy (Nx) as an independent prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with targeted therapies (TTs). (Abstract 517)
Presenting Author: Giuseppe Procopio - Fondazione IRCCS Istituto Nazionale dei Tumori
  BRD. H11 :   Changing treatment paradigms in the era of targeted therapies. (Abstract 518)
Presenting Author: Philipp Marius Papavassilis - Department of Urology, University Hospital Münster
  BRD. H12 :   Temporal changes in the survival of metastatic renal cell cancer patients and the impact of targeted agents: Single center experience. (Abstract 519)
Presenting Author: Mustafa Erman - Hacettepe University Cancer Institute
  BRD. H13 :   Duration of targeted therapy in metastatic renal cell carcinoma patients with ECOG PS>2. (Abstract 520)
Presenting Author: Ilya Tsimafeyeu - Kidney Cancer Research Bureau
  BRD. H14 :   Association of reduced GATA1 mRNA expression with clinicopathology and shortened recurrence-free survival in clear cell renal cell carcinoma. (Abstract 521)
Presenting Author: Inga Peters - Medical School Hannover, Hannover, Germany; Department of Urology and Urologic Oncology
  BRD. H15 :   Neutrophil-lymphocyte ratio in small renal masses. (Abstract 522)
Presenting Author: Wassim Bazzi - Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center
  BRD. H16 :   Late onset of bone metastases as a prognostic parameter in metastatic renal cell cancer (mRCC): A single-center experience in 82 mRCC patients treated with sunitinib. (Abstract 523)
Presenting Author: Philipp Ivanyi - Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School
  BRD. H18 :   The degree of preoperative hydronephrosis to predict pathologic features and oncologic outcomes in high-grade upper tract urothelial carcinoma. (Abstract 525)
Presenting Author: Oussama M. Darwish - The University of Texas Southwestern Medical Center
  BRD. J1 :   Attempting to validate usage of imaging biomarker in a multicentric study to predict PFS in mRCC treated with TKI. (Abstract 526)
Presenting Author: Nathalie Lassau - Institut Gustave Roussy
  BRD. J2 :   Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. (Abstract 527)
Presenting Author: Sarathi Kalra - The University of Texas MD Anderson Cancer Center
  BRD. J3 :   Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted-therapy era. (Abstract 528)
Presenting Author: Sarathi Kalra - The University of Texas MD Anderson Cancer Center
  BRD. J4 :   A phase II study of S-1 in combination with sorafenib in metastatic renal cell carcinoma. (Abstract 529)
Presenting Author: Hideki Sakai - Dpartment of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences
  BRD. J5 :   Changes of pulmonary function test and development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus. (Abstract 530)
Presenting Author: Kwon-Oh Park - Department of Hemato-Oncology, KEPCO Medical Center
  BRD. J6 :   A phase Ib study exploring the combination of everolimus and dovitinib in VEGF-refractory clear cell renal cancer. (Abstract 531)
Presenting Author: Amanda Marie Fitzpatrick - Barts Cancer Institute
  BRD. J7 :   Treatment pattern and prognosis in Japanese patients with metastatic renal cell carcinoma (mRCC) with favorable or intermediate MSKCC risk factors in the era of molecular targeted therapy. (Abstract 532)
Presenting Author: Nobuo Shinohara - Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine
  BRD. J8 :   Markers of sunitinib-resistance in clear cell renal cell carcinoma: A gene expression analysis. (Abstract 533)
Presenting Author: Òscar Reig - Department of Medical Oncology, Hospital Clínic de Barcelona
  BRD. J11 :   High preoperative monocyte-lymphocyte ratio (MLR) as a prognostic factor in nonmetastatic clear cell renal cell carcinoma. (Abstract 534)
Presenting Author: Georg C. Hutterer - Department of Urology, Medical University of Graz
  BRD. J12 :   Clinical outcomes and survival of patients (pts) with sarcomatoid metastatic renal cell carcinoma (smRCC). (Abstract 535)
Presenting Author: Srinivas Kiran Tantravahi - University of Utah, Huntsman Cancer Institute
  BRD. J13 :   Liver metastases as predictors of outcome in renal cell carcinoma (RCC) patients (pts) treated with first-line sunitinib (SU) and sorafenib (SO). (Abstract 536)
Presenting Author: Paolo Grassi - Fondazione IRCCS Istituto Nazionale dei Tumori
  BRD. J14 :   Retrospective study assessing the assotiation of single nucleotide polymorphisms in VEGFR3 and on-target toxicity in patients with advanced renal-CELL carcinoma (RCC) treated with sunitinib. (Abstract 537)
Presenting Author: Jf. Rodriguez-Moreno - Centro Integral Oncológico Clara Campal
  BRD. J15 :   Axitinib: Common questions related to real-world use of a new treatment option in advanced renal cell carcinoma. (Abstract 538)
Presenting Author: Diane Lorraine Borst - Pfizer Oncology
  BRD. J16 :   Interest of percutaneous renal biopsy for small renal masses. (Abstract 539)
Presenting Author: Alexandre Ingels - Institut Mutualiste Montsouris
  BRD. K1 :   Assessment of time from cytoreductive nephrectomy (CN) to initiation of targeted therapy (TT) in patients with metastatic renal cell carcinoma (mRCC). (Abstract 540)
Presenting Author: Winston Vuong - City of Hope Comprehensive Cancer Center
  BRD. K2 :   Major histocompatibility complex class I (MHC 1) expression in clear cell renal cell carcinoma: Correlation with clinical outcome. (Abstract 541)
Presenting Author: Viraj A. Master - Emory University
  BRD. K3 :   Effect of irradiation of renal cell carcinoma (RCC) cell lines on RCC tumor-associated antigen (TAA) specific CD8+ T-cell stimulation. (Abstract 542)
Presenting Author: Gregory Janda - University at Buffalo, The State University of New York
  BRD. K4 :   Metformin use and renal cell cancer outcomes among patients with diabetes. (Abstract 543)
Presenting Author: Farhad Khimani - West Virginia University

^ =This abstract was granted an exception to the ASCO Conflict of Interest Policy restrictions on principal investigators.